<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83659</article-id><article-id pub-id-type="doi">10.7554/eLife.83659</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-232090"><name><surname>Liu</surname><given-names>Can</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293587"><name><surname>Zhou</surname><given-names>Jiawei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293588"><name><surname>Kudlacek</surname><given-names>Stephan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0029-9984</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269938"><name><surname>Qi</surname><given-names>Timothy</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4359-8271</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293590"><name><surname>Dunlap</surname><given-names>Tyler</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-241400"><name><surname>Cao</surname><given-names>Yanguang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3974-9073</contrib-id><email>yanguang@unc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Walczak</surname><given-names>Aleksandra M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS</institution></institution-wrap><country>France</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>25</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83659</elocation-id><history><date date-type="received" iso-8601-date="2022-09-22"><day>22</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-06-01"><day>01</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-04-18"><day>18</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.04.18.488626"/></event></pub-history><permissions><copyright-statement>© 2023, Liu et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Liu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83659-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83659-figures-v1.pdf"/><abstract><p>Effector T cells need to form immunological synapses (IS) with recognized target cells to elicit cytolytic effects. Facilitating IS formation is the principal pharmacological action of most T cell-based cancer immunotherapies. However, the dynamics of IS formation at the cell population level, the primary driver of the pharmacodynamics of many cancer immunotherapies, remains poorly defined. Using classic immunotherapy CD3/CD19 bispecific T cell engager (BiTE) as our model system, we integrate experimental and theoretical approaches to investigate the population dynamics of IS formation and their relevance to clinical pharmacodynamics and treatment resistance. Our models produce experimentally consistent predictions when defining IS formation as a series of spatiotemporally coordinated events driven by molecular and cellular interactions. The models predict tumor-killing pharmacodynamics in patients and reveal trajectories of tumor evolution across anatomical sites under BiTE immunotherapy. Our models highlight the bone marrow as a potential sanctuary site permitting tumor evolution and antigen escape. The models also suggest that optimal dosing regimens are a function of tumor growth, CD19 expression, and patient T cell abundance, which confer adequate tumor control with reduced disease evolution. This work has implications for developing more effective T cell-based cancer immunotherapies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>systems pharmacology</kwd><kwd>pharmacodynamics</kwd><kwd>immunotherapy</kwd><kwd>bispecific T cell engager</kwd><kwd>tumor resistance</kwd><kwd>immunological synapse</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM119661</award-id><principal-award-recipient><name><surname>Cao</surname><given-names>Yanguang</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Modeling the dynamics of immunological synapses informs pharmacodynamics and treatment resistance to bispecific T cell engagers.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Immunotherapy is a type of cancer treatment that helps patients’ immune systems fight cancer, and these therapies include immune checkpoint inhibitors and BiTE. Despite many successes, multiple challenges persist. For instance, only a fraction of patients respond, and many responders eventually relapse (<xref ref-type="bibr" rid="bib35">Nagorsen et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Thakur et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Topp et al., 2014</xref>). The primary pharmacological action of cancer immunotherapies is to activate or reinvigorate the effector T cells to find and engage tumor cells and eventually form cytolytic IS. BiTE, as a unique type of cancer immunotherapy, can redirect T cells to bind specific antigens on tumor cells and form IS. Facilitating the formation of IS through tight intercellular apposition lead to cytolysis of the tumor cell. IS formation is, therefore, a critical step for BiTE pharmacodynamics (<xref ref-type="bibr" rid="bib35">Nagorsen et al., 2012</xref>). Like the IS formed between antigen-presenting cells and T cells, BiTE-induced IS formation between tumor cells and T cells is a precisely orchestrated cascade of molecular and cellular interactions (<xref ref-type="bibr" rid="bib10">Delon and Germain, 2000</xref>; <xref ref-type="bibr" rid="bib39">Roda-Navarro and Álvarez-Vallina, 2019</xref>). Understanding the dynamics of IS formation at the cell population level and factors governing this process hold promise for predicting pharmacodynamics and treatment resistance, one of the most critical issues for immunotherapies.</p><p>The molecular mechanisms of IS formation have been widely studied to identify potential molecular targets for cancer immunotherapy (<xref ref-type="bibr" rid="bib16">Finetti and Baldari, 2018</xref>; <xref ref-type="bibr" rid="bib57">Xiong et al., 2021</xref>). However, IS formation at the macroscopic cell population level extends beyond molecular crosslinking and involves multiple steps of intercellular interactions, such as T cells scanning of target cells in the tumor microenvironment, slowing their motility upon recognition, and establishing intercellular adhesion in response to signals generated by the first encounter (<xref ref-type="bibr" rid="bib14">Dustin and Cooper, 2000</xref>; <xref ref-type="bibr" rid="bib17">Fousek et al., 2021</xref>). Previous pharmacodynamic models of BiTE immunotherapy have focused, almost exclusively, on the mechanisms of molecular crosslinking, with little consideration for macroscopic intercellular interactions (<xref ref-type="bibr" rid="bib4">Betts et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Jiang et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Schropp et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Song et al., 2021</xref>). We sought to investigate how intercellular interactions at the population level could provide further insight into IS formation dynamics, BiTE pharmacodynamics, and mechanisms of resistance.</p><p>Tumor cells reside in dynamic and heterogeneous microenvironments. Suboptimal BiTE efficacy could result from insufficient numbers of effector cells, poor drug penetration into tumor tissue, and antigen loss leading to immune escape. Characterizing IS formation dynamics under diverse conditions, such as varying T cell density, BiTE concentration, antigen binding affinity, and antigen expression, could provide insights into factors determining BiTE pharmacodynamics and possible mechanisms of tumor resistance. <xref ref-type="bibr" rid="bib3">Bell, 1978</xref> developed theoretical models of cell-cell adhesionthat highlighted not only the importance of cell-surface receptors and ligands, but also biophysical factors including receptor diffusivity on the cell membrane and hydrodynamic shearing forces. By now, to our knowledge, there has been no theoretical framework developed to characterize the population dynamics of IS formation, limiting our ability to predict the pharmacodynamics of and resistance to cancer immunotherapies.</p><p>In this study, we applied imaging flow cytometry to quantify BiTE-induced IS formation dynamics under various experimental conditions. Additionally, we developed theoretical models to simulate IS formation on different spatiotemporal scales to interrogate factors influential to this process. After considering patient-specific parameters, models incorporating IS formation dynamics adequately predicted tumor-killing pharmacodynamics in patients. These models revealed trajectories of antigen escape and tumor evolution across anatomical sites and predicted optimal doses and regimens that could confer effective tumor control with reduced disease evolution. Our work shows substantial implications for developing effective T cell-based cancer immunotherapies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Experimental design and theoretical models</title><p>The formation dynamics of the BiTE-induced IS were the focus of this study. As depicted in <xref ref-type="fig" rid="fig1">Figure 1a</xref>, CD3<sup>+</sup> Jurkat was used as effector cells (E) while CD19<sup>+</sup> Raji was used as target cells (T). Jurkat and Raji cells were sorted into three subpopulations, high (H), medium (M), and low (L), based on their membrane expressions of CD3 or CD19, respectively (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Effector and target cells were then co-incubated in the presence of blinatumomab. IS formation dynamics were visualized and quantified by imaging flow cytometry (<xref ref-type="fig" rid="fig1">Figure 1a</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). We quantified the dynamics of IS formation under various experimental conditions, including different cell densities, antigen expressions, incubation durations, E:T ratios, and antibody concentrations. Multiple types of IS were observed and quantified, including ‘typical’ IS with one effector and one target cell (ET) and ‘variants’ with three or more cells engaged, such as ETE, ETT, and ETET.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Schematic of experimental design and theoretical models.</title><p>The study examined the formation dynamics of immunological synapses (IS) elicited by a bispecific T cell engager (BiTE). (<bold>a</bold>) The abundance and dynamics of IS formation were quantified by imaging flow cytometry under various experimental conditions. (<bold>b</bold>) Three mechanistic agent-based models were developed for the comprehensive characterization of cell-cell engagement and tumor-killing effects on different spatiotemporal scales. 3-D, three-dimensional; 2-D, two-dimensional.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Histogram and quantification of high (H), medium (M), and low (L) antigen expression (CD19 and CD3) in cell subpopulations.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Image-based algorithms and gating strategy to identify typical immunological synapse (IS).</title><p>Step 1, gate cells in best focus (R1). Step 2, gate conjugates (R2). Single cells (intermediate area value and high aspect ratio) are excluded. Step 3, gate CD3 and CD19 double positive (R3, FITC+PE+). Step 4, gate conjugates with only one target cell (R4). Step 5, gate conjugates with only one effector cell (R5). This subpopulation consists of doublets with only one effector and one target cell. Step 6, gate immunological synapse (R6). 'Valley’ mask is employed to quantify actin intensity in the region of contact (Bright detail intensity). Co-localization wizard is used to measuring overlap (Bright detail similarity). For technical details, please see the user’s manual of IDEAS.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig1-figsupp2-v1.tif"/></fig></fig-group><p>We developed three mechanistic agent-based models to investigate IS formation and tumor-killing on different spatiotemporal scales. These models were developed in a stepwise fashion and calibrated with experimental or clinical data. As shown in <xref ref-type="fig" rid="fig1">Figure 1b</xref>, the base model was developed for predicting IS formation dynamics within 1 hr. The base model consists of three fundamental components during IS formation: three-dimensional (3D) binding between antibodies and antigens (CD3 or CD19) to form binary complexes, the probability of cell-cell encounter, and cell-cell adhesion driven by two-dimensional (2D) binding to form ternary complexes (CD3-BiTE-CD19) on the cellular membrane. The model structure for the base model is provided in the next section.</p><p>Next, the base model was extended with serial cell-cell engagement dynamics to capture IS formation and tumor-killing for up to 72 hr; we refer to this as the in vitro model. The in vitro model could evaluate the chance for target antigen loss (i.e. CD19), a common mechanism of immune escape, and therapeutic resistance to BiTEs (<xref ref-type="bibr" rid="bib48">Thakur et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Topp et al., 2014</xref>).</p><p>Last, the in vitro model was expanded to include cell-cell engagement in anatomically distinct compartments of the body. This model considered infiltration gradients of T and B cells and organ-to-organ cell trafficking. We refer to this expanded model as the in vivo model. This model integrated patient-specific parameters to predict clinically observed profiles of tumor killing and relapse. The in vivo model was also applied to support the simulation of antigen escape and tumor evolution across anatomical sites and compare dosing regimens for effective tumor control in light of tumor evolution.</p></sec><sec id="s2-2"><title>Model structure (Base model)</title><p>The major mechanism of BiTE pharmacology is to produce ternary complexes (CD3-BiTE-CD19) on opposing cell surfaces, driving IS formation. The dynamics of IS formation are, essentially, two independent and indispensable cellular processes mediated by the cell-cell encounter and cell-cell adhesion. Compared to molecular scale-focused pharmacodynamics models of BiTEs (<xref ref-type="bibr" rid="bib4">Betts et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Jiang et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Schropp et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Song et al., 2021</xref>), our models highlight the importance of these two cellular processes for IS formation in the context of macroscopic and biophysical forces (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The base model included three essential steps to describe the process of immunological synapses (IS) formation induced by bispecific T cell engagers (BiTEs).</title><p>Step 1: three-dimensional (3D) antibody-antigen binding in the media to form a binary complex; Step 2: cell-cell encounter, with encounter probability (Pe) dictated by cell motility and density; Step 3: cell-cell adhesion and IS formation, with adhesion probability (Pa) driven by the density of ternary complexes formed on the cell-cell contact area (two-dimensional (2D) binding) during contact. Newly formed typical IS had a chance to engage additional free effector or target cells to form an IS variant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig2-v1.tif"/></fig><p>In the base model (<xref ref-type="fig" rid="fig2">Figure 2</xref>), three essential steps are defined: antibody-antigen binding to form binary complexes (BiTE-CD3 and BiTE-CD19) (step 1), effector-target cell encounter probability defined as a function of cell mobility and density (step 2), and effector-target cell adhesion probability defined as a function of ternary complexes formed during contact (step 3). Model equations are provided in Appendix 1. Antibody-antigen binding to form binary complexes were assumed to be 3D processes that reached rapid equilibrium prior to cellular-scale events. Free effector cells were assumed to follow Brownian motion (<xref ref-type="bibr" rid="bib6">Celli et al., 2012</xref>) and encounter target cells at a probability proportional to cell density and motility in the incubation environment (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>After the cell-cell encounter, the probability of adhesion was modeled as a function of the number of ternary complexes (CD3-BiTE-CD19) formed between cells during the duration of contact. Cell-cell complexes with a high number of ternary complexes would, therefore, have a higher probability to adhering and eventually forming IS. Ternary complex formation on opposing cells was assumed to be restricted to the cell membrane (2D binding; <xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>). The derivation of 2D binding affinities is provided in Appendix 1.5. Cells that failed to adhere upon encounter (futile contact) were assumed to diffuse away and become free to repeat the same process. Two cells engaged in a typical IS were also considered capable of engaging additional effector or target cells to become an IS variant, per our experimental observations (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The model considered IS variants comprising up to four cells.</p><p>Model details and parameters for the base, in vitro and in vivo models are provided in materials and methods, Appendix 1, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s2-3"><title>Effects of BiTE concentration, cell density, and antigen expression on IS formation</title><p>IS formation dynamics were quantified by imaging flow cytometry. Representative images of non-engaged (futile contact), typical IS, and multiple IS variants are shown in <xref ref-type="fig" rid="fig3">Figure 3a</xref>. Contact between the effector and target cells was evaluated in brightfield and FITC + PE channels. Their interfaces were classified as bona fide IS when there was a high intensity of actin (red) at the contact site, as F-actin is known to polymerize and locally concentrate at sites of the interface (<xref ref-type="bibr" rid="bib14">Dustin and Cooper, 2000</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Dynamics of immunological synapse (IS) formation induced by bispecific T cell engager (BiTE) under different conditions.</title><p>(<bold>a</bold>) Representative image of non-engagement (futile encounter), typical IS, and other IS variants. Green (FITC), effector cells (E); Yellow (PE), target cells (T). (<bold>b–i</bold>), The effects of drug concentration (<bold>b</bold>), incubation duration (<bold>c</bold>), antigen density (<bold>d, e</bold>), cell density (<bold>f, g</bold>), and E:T ratio (<bold>h, i</bold>) on IS formation. The base model was applied to simulate IS formation under different conditions. Observations are dots (with SE) and model simulations are solid curves. 2 X, 2 × 10<sup>6</sup> total cells/mL; E:T(1), E:T ratio = 1; CD3(L), CD3 expression (Low); CD3(H), CD3 expression (High); CD19(M), CD19 expression (medium); 5, 20, 100 ng/mL, blinatumomab concentration; 60 min, incubation duration. All samples were biologically triplicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Performance of the base model (observation vs simulation).</title><p>Observed and model predicted fraction (%) of effector cells engaged in immunological synapse (IS). solid line, y=x.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>The effect of binding affinity on bispecific T cell engager (BiTE)-mediated cell-cell engagement.</title><p>The base model was applied to perform simulations. K<sub>D</sub>, dissociation constant; gray vertical line, the K<sub>D</sub> value of blinatumomab;. 2 X, 2 × 10<sup>6</sup> total cells/mL; E:T(1), E:T ratio = 1; CD3(L), CD3 expression (Low); CD19(M), CD19 expression (medium); 5, 20, 100 ng/mL, blinatumomab concentration; 60 min, incubation duration.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig3-figsupp2-v1.tif"/></fig></fig-group><p>To investigate the key influential factors of IS formation, we explored multiple experimental conditions by varying BiTE concentration (0.65–2000 ng/ml), incubation duration (0–60 min), antigen expression (three levels for either CD3 or CD19), cell density (0.7–8 million total cells/mL), and E:T ratio (0.05–6) (<xref ref-type="fig" rid="fig3">Figure 3b–i</xref>). The fraction (%) of effector cells engaged in IS was quantified to inform IS formation dynamics. We also ran these experiments virtually using the base model to test the model’s predictive performance and to explore mechanistic hypotheses.</p><p>In <xref ref-type="fig" rid="fig3">Figure 3b–i</xref>, the observations (symbols) and model simulations (lines) overlapped, indicating good base model performance. IS formation in vitro exhibited a bell-shaped relationship to BiTE concentration (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). The model predicted this bell-shaped relationship and revealed that high BiTE concentrations (&gt;100 ng/ml) would reduce the formation of ternary complexes, partly because individual antigens (CD3 and CD19) were almost completely occupied by one arm of the BiTE, limiting crosslinking with opposing cells (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>). IS formation increased over time and plateaued around 60 min (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). We, therefore, restricted our incubation to 60 min considering IS quantification could be biased by serial cell-cell engagements and potential cell lysis (<xref ref-type="bibr" rid="bib17">Fousek et al., 2021</xref>).</p><p>The effect of CD3 expression on IS formation was relatively small, especially at low BiTE concentrations (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). The model revealed that only a small fraction of CD3 was occupied; therefore, we concluded CD3 expression was not a key driver of IS formation at low BiTE concentrations. The base model underpredicted the effect of CD3 expression on IS formation at 100 ng/ml BiTE concentration, which is partially because of the rapid CD3 downregulation upon BiTE engagement and assay variation across experimental conditions. In contrast, we found CD19 expression on target cells profoundly impacted IS formation (<xref ref-type="fig" rid="fig3">Figure 3e</xref>). These results were also predicted by the base model.</p><p>Our model predicted that cell density would also be critical to IS formation on a per-cell basis. Increasing total cell density (E+T) from 1 to 8 million per ml at an E:T ratio around 1:1 drastically boosted IS formation from 3.1 to 15.3% at 20 ng/ml BiTE and 3.9 to 27.8% at 100 ng/ml BiTE (<xref ref-type="fig" rid="fig3">Figure 3f</xref>). IS formation was further increased with high CD3-expressing effector cells at high cell densities (<xref ref-type="fig" rid="fig3">Figure 3g</xref>).</p><p>The E:T ratio also played a pivotal role in IS formation. Changing the E:T ratio led to variations in the fraction of effector and target cells involved in IS formation, as predicted by the model. With higher E:T ratios, a greater fraction of target cells but a lower fraction of effector cells was involved in IS formation (<xref ref-type="fig" rid="fig3">Figure 3h and i</xref>).</p><p>Overall, we found multiple factors to be influential to IS formation. The model reasonably recapitulated IS formation dynamics under various conditions (<xref ref-type="fig" rid="fig3">Figure 3b–i</xref>). The goodness of model predictions is provided in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>. With good model predictability, we further investigated the influence of CD3 and CD19 binding affinities (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a and b</xref>). Counterintuitively, higher affinities to CD3 resulted in higher predicted IS formation at low BiTE concentration (e.g. 0.58% and 0.41% at 0.65 ng/mL with K<sub>D,CD3</sub> = 2.6×10<sup>-10</sup> and 2.6×10<sup>-7</sup> respectively, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b</xref>), but lower predicted IS formation at high BiTE concentration, which is perhaps due to the oversaturation of both CD3-BiTE and CD19-BiTE and higher induction of CD3 downregulation. Reduced IS formation at high CD3 affinities also resulted in a bell-shaped relationship (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b</xref>). Notably, there are papers reporting that high CD3 affinity may result in negative effect on BiTE safety and clinical efficacy (<xref ref-type="bibr" rid="bib7">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">Dang et al., 2021</xref>). Our model suggested that blinatumomab has an affinity for CD3 within the optimal range of 10<sup>–7</sup> – 10<sup>–6</sup> M. In contrast, BiTEs with higher affinity to CD19 were predicted to enhance IS formation (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2c and d</xref>).</p></sec><sec id="s2-4"><title>IS variants were prevalent and well-predicted by the base model</title><p>Many types of IS variants were observed in the experimental system. In total, six types of IS were quantified, including typical IS (ET), ETE, ETT, ETET, ETEE, and ETTT. IS variants with more than four cells were not analyzed in our study, nor included in the base model, due to their low abundance. The frequency of these variants was recorded and compared under each experimental condition.</p><p>Depending on the experimental condition, approximately 12–25% of IS observed were IS variants, although this increased up to 50% under condition 5 due to high cell density and BiTE concentration (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). Among these IS variants, ETE and ETT were the most frequently observed, accounting for more than 60% of total IS variants formed under all conditions (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). Conditions 5 and 11 showed high ETE frequencies due to a high E:T ratio (6:1), while conditions 6 and 12 showed high ETT frequencies due to a low E:T ratio (1:5.8). The base model well predicted the relative fraction of each IS variant under all tested conditions (<xref ref-type="fig" rid="fig4">Figure 4a, b</xref>). In general, the fraction of IS variants increased with total IS abundance. The positive correlation between the fraction of IS variants and effector cells involved in IS was well predicted by the base model (<xref ref-type="fig" rid="fig4">Figure 4c</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Multiple types of immunological synapses (IS) variants were observed and well-predicted by the base model.</title><p>In total, six types of IS were quantified, including typical IS (ET), ETE, ETT, ETET, ETEE, and ETTT. (<bold>a</bold>) The fraction of typical IS and variants under different conditions; (<bold>b</bold>) The composition of IS variants (ETE, ETT, ETET, ETEE, ETTT) under different conditions; (<bold>c</bold>) The positive correlation between the fraction of IS variants (% of total IS) and total IS formation (effector cell % engaged). The formula and R<sup>2</sup> of linear regressions are shown. (<bold>d</bold>) The E:T ratios involved in total IS and IS variants. Experimental setup: Condition 1, 2 X, E:T(1), CD3(L), CD19(M), 100 ng/mL, 60 min; Condition 2, 4 X, E:T(1), CD3(L), CD19(M), 100 ng/mL, 60 min; Condition 3, 2 X, E:T(1), CD3(H), CD19(M), 100 ng/mL, 60 min; Condition 4, 2 X, E:T(1), CD3(L), CD19(L), 100 ng/mL, 60 min; Condition 5, 4 X, E:T(6), CD3(L), CD19(M), 100 ng/mL, 60 min; Condition 6, 4 X, E:T(0.17), CD3(L), CD19(M), 100 ng/mL, 60 min; Conditions 7–12 are the same as Conditions 1–6, except with lower bispecific T cell engager (BiTE) concentrations (20 ng/mL).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig4-v1.tif"/></fig><p>The E:T ratios of IS variants from all co-incubation samples were pooled for comparison (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). The median E:T ratio in total IS was about 1.0. When excluding typical IS, this ratio increased to 1.1 for the remaining IS variants, suggesting slightly more effector cells were involved in IS variant formation than target cells, in line with model predictions.</p></sec><sec id="s2-5"><title>The in vitro model predicted antigen escape and organ reservoirs</title><p>Effector T cells detach from IS and re-engage with other target cells in a process called serial cellular engagement. These effector T cells are also known as ‘serial killers’ (<xref ref-type="bibr" rid="bib17">Fousek et al., 2021</xref>; <xref ref-type="bibr" rid="bib40">Rogala et al., 2015</xref>). We extended the base model to incorporate IS detachment and re-engagement (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). The in vitro model simulated IS formation and cellular cytotoxicity for up to 72 hr. With serial engagement and killing, the fraction of target cell lysis increased considerably, even at low BiTE concentrations (<xref ref-type="fig" rid="fig5">Figure 5b</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The in vitro model predicted tumor evolution in time and space.</title><p>(<bold>a</bold>) Scheme of cell detachment and serial engagement in the in vitro model. Immunological synapses (IS) duration is set to 150 min. Pe, encounter probability, Pa, adhesion probability; (<bold>b</bold>) Long-term simulation (72 hr) of target cell depletion across drug concentrations; (<bold>c–d</bold>) The effects of drug concentration (<bold>c</bold>) and incubation time (<bold>d</bold>) on CD19 expression. Dashed line, a pre-defined threshold value of CD19 expression for 15% target cell depletion within 72 hr (initial setup: 2 X, E:T(1), CD3(L), 0.65 ng/mL, 72 h). Ctrl, the initial distribution of CD19 expression in the target cell population. (<bold>e–f</bold>) the effects of effector and target cell density on target cell depletion (%). Dots indicated the effect and target cell densities in healthy human organs. White color, 15% target cell depletion. BM, bone marrow; LN, lymph nodes; SP, spleen; Remainder, all the rest of the non-lymphoid organs. Initial setup: CD3(L), CD19(M) for (<bold>e</bold>), CD19 (M/20) for (<bold>f</bold>), 0.65 ng/mL, 72 h.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The effects of ET ratio (<bold>a</bold>), cell density (<bold>b</bold>), and binding affinity (<bold>c</bold>) on CD19 evolution.</title><p>The in vitro model was applied to perform simulations. Dashed line, the threshold value of CD19 expression for 15% target cell depletion within 72 h (initial setup: 2 X, E:T(1), CD3(L), 0.65 ng/mL, 72 h). Ctrl, initial CD19 distribution in the target cell population. K<sub>d</sub>, dissociation constant; 2 X, 2 × 10<sup>6</sup> total cells/mL; E:T(1), E:T ratio = 1; CD3(L), CD3 expression (Low); CD19(M), CD19 expression (medium); 0.65, 20 ng/mL, blinatumomab concentration; 72 h, incubation duration.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>The effects of effector and target cell density on target cell depletion (%) at 72 h.</title><p>Simulations were performed by the in vitro model. Dots indicated the effect and target cell densities in healthy human organs. White color, 15% target cell depletion. BM, bone marrow; LN, lymph nodes; SP, spleen; Remainder, all the rest of non-lymphoid organs. Initial setup: CD3(L), CD19(M) for a, CD19 (M×4) for b, CD19 (M/4) for c, CD19 (M/20) for d, 0.65 ng/mL, 72 h.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Different effects of CD19 on cellular and molecular processes.</title><p>(<bold>a–b</bold>) Different effects of target cell density and CD19 expression on target cell depletion amount (<bold>a</bold>) and fraction (<bold>b</bold>). The in vitro model was used in the simulation. Initial setup: CD3(L), effector cell (1 X), target cell (X/20 to 500 X), CD19 expression (M/20 to 500 M), 0.65 ng/mL, 72 h. Total CD19 in the system was jointly influenced by CD19 expression per target cell and target cell density. CD19 expression influenced cell lysis to a similar extent as target cell density when both factors were low (e.g. CD19 expression &lt;M, target cell density &lt;X in (<bold>a</bold>)). However, further increase of CD19 expression on cell membrane did not further improve cell lysis (e.g. from point A to point C), indicating maximum ternary complexes at each interface have been reached. In contrast, the increase of target cell density continuously promotes cell lysis, e.g., from point A to B, due to enhanced probability of cell-cell encounter. When the target cell density reaches extremely high (&gt;50 X), cell lysis started to decrease, resulting from fewer cell-cell adhesion events due to insufficient bispecific T cell engager (BiTE) concentration. As shown, although total CD19 in the system at point B and C are identical (10 × M × X), different cell lysis level is yielded, supporting different effects of CD19 on cellular and molecular processes. (<bold>c</bold>) Effects of B cell density and CD19 expression on B cell depletion in vivo. In each group, the change of total CD19 density from the reference (1 X, 200 B cells/μL × 30,000 CD19/cell) was achieved through changing B cell density (red bar) or CD19 expression (gray bar). Their effects on B cell depletion amount were simulated by the in vivo model. Initial setup for reference (1 X): T cell (200 /μL), B cell (200 /μL), CD3 (50, 000 /cell), CD19 (30, 000 /cell), 0.73 ng/mL, 72 h. Different effects of CD19 on cellular and molecular processes have been confirmed by the in vivo model. Similarly, the increase of CD19 expression within low-level range (3 × 10<sup>3</sup>–3 × 10<sup>5</sup> CD19/cell from 0.1X to 10X) constantly improved cell depletion, as ternary complexes formation at each interface increased with CD19 expression. By contrast, a bidirectional effect was shown by increasing B cell density, owing to enhanced probability of cell-cell encounter at the population level and then insufficient BiTE concentration. Herein, B cell density at 10 X (2000 /μL) in the blood indicates extremely high organ B cell density in the model, e.g., spleen (~9 × 10<sup>8</sup> /mL) and lymph nodes (~3 × 10<sup>8</sup> /mL).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig5-figsupp3-v1.tif"/></fig></fig-group><p>Importantly, the in vitro model predicted tumor evolution toward populations with low CD19 expression (i.e. antigen escape). Approximately 10–20% of patients who relapse after blinatumomab treatment experience antigen escape, which decreases the efficacy of subsequent anti-CD19 CAR-T cell therapy (<xref ref-type="bibr" rid="bib5">Braig et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Pillai et al., 2019</xref>). As shown in the model, tumor cells with lower CD19 expression had a lower chance of being engaged by effector cells and thus a higher probability of surviving (<xref ref-type="fig" rid="fig5">Figure 5c, d</xref>). The speed of evolution was predicted to increase at greater BiTE concentrations (<xref ref-type="fig" rid="fig5">Figure 5c</xref>) and accelerate over time (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). The effect of E:T ratio, cell density, and antigen affinity on tumor evolution were also simulated (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Notably, greater IS formation led to more extensive evolution toward lower CD19-expressing cells.</p><p>The impact of cell density at clinically relevant BiTE concentrations was also interrogated (<xref ref-type="fig" rid="fig5">Figure 5e, f</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Notably, an increase of effector cell density resulted in higher fractions of target cell lysis at 72 hours. However, a higher density of target cells did not markedly diminish the fraction of target cells lysed at a given effector cell density, due to a compensatory increase in the probability of cell-cell encounter probability per effector cell. When target cell density was extremely high (e.g., &gt; 5×10<sup>6</sup>/mL with medium CD19 expression at 1.45×10<sup>5</sup>/cell in <xref ref-type="fig" rid="fig5">Figure 5e</xref>), lysis fraction decreased, as the low BiTE concentration may have become a limiting factor for IS formation. We used organ-specific effector and target cell abundance (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>) to compare the predicted gradient of cell lysis across organs (<xref ref-type="fig" rid="fig5">Figure 5e, f</xref><italic>,</italic> <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Higher target cell lysis was predicted in lymph nodes and the spleen due to the abundance of effector cells in these organs. The bone marrow and all the rest of non-lymphoid organs (the remainder) showed restricted cell lysis primarily due to their relatively low abundance of effector cells (<xref ref-type="fig" rid="fig5">Figure 5f</xref>). The model also predicted that some organs like the bone marrow may become tumor cell sanctuary sites, providing space for tumor cell survival and adaptation, thereby increasing the likelihood of treatment resistance.</p></sec><sec id="s2-6"><title>The in vivo model predicted clinical outcomes and tumor evolution across anatomical sites</title><p>We developed the in vivo model by defining IS formation dynamics in organs and cell trafficking across organ compartments (<xref ref-type="fig" rid="fig6">Figure 6a</xref>, Materials and methods, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b and c</xref>). We used the model to simulate cell lysis in each organ and tumor-killing profiles throughout the body. Organ-specific cell lysis is highly dependent on relative IS formation dynamics and thus is a function of organ-specific effector (T cell) and target (B cell) populations, as well as BiTE exposure.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The in vivo model predicted clinical pharmacodynamics and tumor evolution across anatomical sites.</title><p>(<bold>a</bold>) Scheme of organ compartment and cell trafficking. Remainder, all the rest of the non-lymphoid organs; k<sub>B cell</sub>, the turnover rate of B cell; k<sub>traff, in</sub> and k<sub>traff out,</sub> B cell trafficking rate. For parameters and trial information, see Materials and methods, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b and c</xref>; (<bold>b–e</bold>) Observed and simulated patient B cell profiles in blood; (<bold>f</bold>) Simulated CD19 evolution in non-responder patients of trial MT103-211; (<bold>g</bold>) Simulated cell lysis potency for each organ in trial MT103-104; (<bold>h</bold>) Simulated baseline (day 0), and post-treatment (day 7 and 14) B cell organ distribution in patients with OS &gt;30 months of trial MT103-206. Bar plot, simulated baseline and post-treatment tumor burden; (<bold>i–l</bold>) Sensitivity analyses for the impact of drug concentration (<bold>i</bold>), T cell density (<bold>j</bold>), B cell density (<bold>k</bold>), and CD19 expression (<bold>l</bold>) on B cell depletion. T cell density change is allowed in the simulations (<bold>b–e</bold>), details see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>. BM, bone marrow; LN, lymph nodes; OS, overall survival; Rmd, remainder.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>The effect of blood flow on the production and stability of immunological synapses (IS).</title><p>(<bold>a</bold>) Cell co-culture was conducted at different flow velocities, producing different shear stresses to mimic the effect of blood flow. Initial setup: 2 X, 2 × 10<sup>6</sup> total cells/mL; E:T(1), E:T ratio = 1; CD3(L), CD3 expression (Low); CD3(M), CD3 expression (medium); CD19(M), CD19 expression (medium); 100 ng/mL, blinatumomab concentration; 60 min, incubation duration. (<bold>b</bold>) Cell incubation was conducted at static condition (initial setup: 2 X, E:T(1), CD19(M), CD3(L), 100 ng/mL, 60 min, shear stress = 0) and followed by adding different shear stresses (5 min) to test the stability of pre-existing IS. The reference line (100%) indicated the frequency of the effector cells engaged at static condition.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Simulated baseline (day 0), and post-treatment (day 7 and 14) B cell organ distribution in patients of trial MT103-206.</title><p>The in vivo model was applied to perform the simulations. Bar plot showed the simulated tumor burden at baseline and post-treatment. BM, bone marrow; LN, lymph nodes; OS, overall survival; Rmd, remainder, all the rest of the non-lymphoid organs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig6-figsupp2-v1.tif"/></fig></fig-group><p>In the in vivo model, the blood compartment serves merely as a trafficking route and does not mediate IS formation and detachment (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). This assumption was supported by our observation that negligible IS was formed under shear stress forces approximating those experienced under blood flow (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1a</xref>). Once formed, IS in the blood are unlikely to be broken through shear stress (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1b</xref>). Blood B cell levels reflected the systemic average. Although only 2% of lymphocytes are present in the blood, blood flow can transport about 5 × 10<sup>11</sup> lymphocytes each day – comparable to the total number of lymphocytes in the body (<xref ref-type="bibr" rid="bib56">Westermann and Pabst, 1992</xref>).</p><p>Patients show mixed responses to BiTE immunotherapy. Some patients exhibit complete tumor eradication while others have negligible responses. By adopting patient-specific parameters, such as BiTE dosing regimens and T cell proliferation profiles, the in-vivo model reasonably predicted B-cell depletion profiles in patients (<xref ref-type="bibr" rid="bib2">Bargou et al., 2008</xref><italic>;</italic> <xref ref-type="bibr" rid="bib29">Klinger et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Zhu et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Zhu et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Zugmaier et al., 2015</xref>) treated with blinatumomab in multiple clinical trials (<xref ref-type="fig" rid="fig6">Figure 6b–e</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b,c</xref>). In the trials MT103-211 and MT103-206, rapid accumulation of T cells in the blood was observed in responders but not non-responders (<xref ref-type="bibr" rid="bib62">Zhu et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Zugmaier et al., 2015</xref>). The model could account for these patient-specific T cell profiles and distinguish between responding and non-responding patients (<xref ref-type="fig" rid="fig6">Figure 6d, e</xref>).</p><p>Like the in vitro model, the in vivo model also predicted evolution toward low CD19-expressing cell populations over time, as shown in non-responders in MT103-211 (<xref ref-type="fig" rid="fig6">Figure 6f</xref>). This process is inevitable; the stronger the therapeutic pressure, the lower CD19-expression in the surviving cell population. The fraction of low CD19-expressing cells increases over time while the efficiency of tumor cell lysis decreases, leading to a gradual loss of drug sensitivity.</p><p>We finally explored tumor evolution across anatomical sites and characterized the spatial gradients of cell lysis. The lymph node, spleen, and lung showed higher fractions of cell lysis than the gut, bone marrow, and remainder (<xref ref-type="fig" rid="fig6">Figure 6g</xref>). More than 45% of malignant cells in the system were lysed in the lymph nodes and around 30% were eradicated in the spleen. Lytic fractions were higher than their respective baseline levels in both organs, confirming enhanced tumor killing mediated by BiTE. In contrast, the lytic fraction in the bone marrow was lower under treatment than at baseline (<xref ref-type="fig" rid="fig6">Figure 6g</xref>), indicating poor tumor lysis efficiency. The anatomical differences in the efficiency of cell lysis affected B cell biodistribution after BiTE treatment in patients (<xref ref-type="fig" rid="fig6">Figure 6h</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). The relative anatomical distribution of B cells also shifted considerably over time. In high responders (OS &gt;30 months, MT103-206), over 99% of B cells were eradicated, particularly in organs with high predicted lysis (lymph nodes and spleen). In the bone marrow, a small fraction of B cells survived that exhibited considerably lower CD19 expression than the original cell population. Unfortunately, the surviving cell populations gradually repopulated the bone marrow, leading to B cell rebound and eventually patient relapse. By contrast, non-responders had a lower fraction of B cell lysis by day 14, with B cell distribution profiles remaining similar to the baseline (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p><p>Sensitivity analyses confirmed that baseline tumor burden, drug concentration, cytotoxic T cell infiltration, and CD19 expression were critical to patient response (<xref ref-type="fig" rid="fig6">Figure 6i - l</xref>).</p></sec><sec id="s2-7"><title>The in vivo model predicted optimal dosing regimens for blinatumomab</title><p>We applied the in vivo model to simulate B cell-killing efficacy and CD19 evolution during blinatumomab treatment and compared different doses and regimens (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). The initial plasma B cell abundance was assumed to be 200 cells/µL, with varying levels of growth rates. Under the approved dose (i.e. the high dose) and scheme 1, tumor-killing profiles were highly dependent upon tumor growth rate and baseline T cell abundance (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). Tumors gradually accumulated resistance to treatment, especially fast-growing tumors. For slow-growing tumors with low T cell baseline, the medium dose showed a comparable tumor-killing effect but resulted in less CD19 evolution than the high dose (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). In contrast, for slow-growing tumors with high T cell abundance, the high dose exhibited almost complete tumor control and much less CD19 loss than the medium dose (<xref ref-type="fig" rid="fig7">Figure 7d</xref>). The high dose showed similar efficacy at the two dosing schemes, but scheme 2 had fewer total doses. For fast-growing tumors, CD19 loss was significant, regardless of dose and regimen (<xref ref-type="fig" rid="fig7">Figure 7e</xref>). The medium dose in scheme 2 elicited less CD19 loss and better tumor control than scheme 1. <xref ref-type="fig" rid="fig7">Figure 7f</xref> summarized the favorable dosing regimen under each condition. We found that the approved dose or regimen was suboptimal for most slow-growing tumors; rather, the medium dose or dosing scheme 2 could reach similar efficacy with slower CD19 evolution. The high dose was required for almost all fast-growing tumors, with the only exception being patients with high CD19 expression and high T cell abundance at baseline who received more benefit from the medium dose at scheme 2. Overall, our in vivo model, through defining IS formation dynamics across anatomical sites in the system, could predict BiTE pharmacodynamics and changes in CD19 expression over time, and identify optimal dosing strategies based on baseline tumor characteristics.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>The dose and regimen of bispecific T cell engager (BiTE) strongly influenced tumor control and CD19 evolution.</title><p>(<bold>a</bold>) Three doses (high, medium, and low) and regimens (scheme 1 and 2) were evaluated in the simulations. Starting doses were applied in the first week of cycle 1 only. The high dose with scheme 1 is the clinically approved dose and regimen of blinatumomab for the treatment of B cell acute lymphoblastic leukemia; (<bold>b</bold>) Simulated blood B cell profiles under different T:B ratios and B cell growth rates in 22-week treatment; (<bold>c–e</bold>) Different dose levels, and schemes were explored in respective conditions. Simulated blood B cell profiles and CD19 evolution were shown. Gray line and shaded regions represent baseline CD19 expression; (<bold>f</bold>) The favorable dosing regimen under each condition. The favorable dosing regimen was determined by comparing B cell killing efficacy, CD19 evolution, and total dose, in this order of priority, respectively. B (200 /μL), baseline B cell density in blood is assumed to be 200 /μL; High (<bold>b–e</bold>) and low CD19 expressions were the mean level of CD19 expression per B cell and set as 3 × 10<sup>4</sup> and 1 × 10<sup>4</sup>, respectively; High growth and low growth of B cells were set to 0.071 /day and 0.0071 /day; T cell density change is not included in this proof-of-concept simulations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The clinical efficacy of BiTE immunotherapy remains suboptimal, with many of the patients who initially respond eventually experiencing disease relapse. Understanding IS formation, a crucial step in many T cell immunotherapy’s mechanisms of action, can yield insights into the pharmacodynamics of BiTEs and subsequent treatment resistance. This study used an experimentally and theoretically integrated approach to examine IS formation dynamics induced by BiTEs on a population level. The abundance of IS caused by BiTEs was quantified using imaging flow cytometry, and the dynamics of IS formation were simulated with theoretical models. By defining IS formation as a spatiotemporal orchestration of molecular and cellular interactions, our theoretical models recapitulated the experimental data well. Notably, the models predicted antigen escape to be a common mechanism of resistance to BiTE immunotherapy. Tumor cells with low antigen expression accumulated over time, leading to treatment resistance and eventual disease relapse. The anatomical heterogeneity of T cell infiltration and E:T ratios across organs also conferred heterogeneous degrees of cell lysis. In particular, a subset of tumor cells in ‘sanctuary sites,’ such as the bone marrow, may be relatively protected from effector cell lysis and fuel tumor evolution and disease relapse.</p><p>IS formation induced by BiTEs is determined mainly by two cell-scale interaction processes: cell-cell encounter and adhesion. Cell-cell encounter is the first, and in many instances, the rate-limiting step to IS formation. For simplicity, the models assume random cell motion without consideration for directed or chemotactic movement (<xref ref-type="bibr" rid="bib6">Celli et al., 2012</xref>). Cell density is another critical factor; cell encounter probability could become the rate-limiting step for IS formation when the target cell density is sufficiently low that effector cells have little chance of encountering target cells. This could be particularly challenging for patients with minimal residual disease. When effector cell density is low, as in the bone marrow, tumor cells have a higher chance of surviving for long enough to develop immune evasion mechanisms, leading to treatment resistance. On the other hand, when target cell density is extremely high within an organ, target cell lysis may be compromised by insufficient antibody concentrations at clinically utilized doses (<xref ref-type="fig" rid="fig5">Figure 5e and f</xref>). This is consistent with clinical observations that the efficacy of blinatumomab is much higher in patients with relatively low tumor burden (<xref ref-type="bibr" rid="bib50">Topp et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Viardot and Bargou, 2018</xref>).</p><p>Synapse formation is a set of precisely orchestrated molecular and cellular interactions. Our model merely investigated the components relevant to BiTE pharmacologic action and thereby serve as a simplified representation of this process. The molecular crosslinking between BiTEs and antigens affects the probability of cell-cell adhesion upon encounter. Drug concentration, binding affinity, and antigen expression are critical determinants of this process. Adhesion molecules such as CD2-CD58, integrins, and selectins, are critical for cell-cell interaction. The model did not consider specific roles played by these adhesion molecules, which were assumed constant across cell populations. The model performed well under this simplifying assumption.</p><p>Many studies have reported a bell-shaped drug concentration-response profile for BiTE immunotherapy (<xref ref-type="bibr" rid="bib4">Betts et al., 2019</xref>; <xref ref-type="bibr" rid="bib11">Douglass et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Schropp et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Van De Vyver et al., 2021</xref>), with the primary mechanism underlying the phenomenon being the oversaturation of T cell receptors at high BiTE concentrations. The theoretical model reported herein also predicts a bell-shape concentration – IS curve, but the predicted curve peaked at higher antibody concentrations if not including the possibility of CD3 down-regulation by effector cells upon antibody engagement.</p><p>We explored the different effects of CD19 on cellular and molecular processes. Total CD19 in the system was jointly influenced by CD19 expression on membrane and target cell density. CD19 expression influenced cell lysis to a similar extent as target cell density when both factors were low (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3a</xref>). However, an increase of CD19 expression beyond 3 × 10<sup>5</sup> receptors/cell did not further improve cell lysis. In contrast, target cell densities seemed to have a bidirectional effect on cell lysis. At low levels, escalating cell densities enhanced the probability of cell-cell encounter, while at high target cell densities, BiTE concentrations were insufficient to mediate meaningful IS formation, resulting in fewer cell-cell adhesion events and less cell lysis (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3a, b</xref>). This is consistent with clinical simulations (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3c</xref>). The different roles of CD19 expression and target cell density highlight the importance of cellular-scale interactions to IS formation that cannot be appropriately described by molecular crosslinking alone. Because of these cellular processes, our theoretical models fundamentally differ from previous BiTE pharmacodynamics models that consider molecular crosslinking only (<xref ref-type="bibr" rid="bib4">Betts et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Jiang et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Schropp et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Song et al., 2021</xref>). In our models, molecular crosslinking caused by BiTE, i.e., ternary complex formation, drove cell-cell adhesion events, whereas cell-cell encounters were modeled as an independent process.</p><p>Heterogeneity of CD19 antigen expression is a critical factor in BiTE-induced IS formation. Target cells with lower antigen expression had a lower probability of adhesion to T cells and thus a greater chance of survival. The theoretical models suggest that tumor evolution is an inevitable consequence in treatment, and that the stronger the therapeutic selection pressure, the more tumor cell populations evolve away from their pretreatment phenotype. Ultimately, the surviving tumor cells shift toward a low antigen expression population in a process known as antigen escape. Antigen escape is a common mechanism of resistance to T cell-based immunotherapy (<xref ref-type="bibr" rid="bib1">Aldoss et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Mejstríková et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Samur et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Topp et al., 2014</xref>; <xref ref-type="bibr" rid="bib58">Xu et al., 2019</xref>); however, the speed of tumor evolution toward antigen escape remains hard to predict. Through defining the formation of IS, our models show a proof of concept for predicting the trajectory of antigen escape based on baseline antigen expression, more validations of our models are warranted.</p><p>Non-uniform tumor lysis effect across organs represents another barrier for therapy. Provided an anatomical space with few effector cells, tumor cells might use the bone marrow as a sanctuary site within which IS formation is infrequent. Insufficient selective pressure from effector cells might allow the regeneration of a newly resistant population of tumor cells that then repopulate other organs and accelerate systemic disease progression. This speculation is consistent with the clinical observation that patients under BiTE treatment often have relapses first detected in the bone marrow (<xref ref-type="bibr" rid="bib32">Locatelli et al., 2022</xref>). Of note, the inadequate tumor lysis in the bone marrow might also be explained by tissue-specific differences in chemokine gradients that hinder cell-cell interaction and adhesion.</p><p>We used the in vivo model to compare different doses and schedules of blinatumomab. We found that tumor baseline characteristics, including tumor growth rate, CD19 expression, and T cell abundance, greatly influenced tumor-killing pharmacodynamics, tumor evolution, and consequentially, the ideal dosing regimen. The clinically approved dose and regimen might become suboptimal for most slow-growing tumors. The medium dose or mild regimen could maintain an optimal balance between tumor-killing and evolutionary pressure (<xref ref-type="fig" rid="fig7">Figure 7f</xref>). However, it was not always the case that higher dose amounts (i.e. higher therapeutic pressure) resulted in faster tumor evolution. For slow-growing tumors with sufficient T cells (<xref ref-type="fig" rid="fig7">Figure 7d and f</xref>), the high dose with regimens 1 or 2 could cause nearly complete tumor eradication, thereby resulting in negligible selection and limiting the total population size remaining for evolution. Faster and greater reductions in population size conferred by high doses might, therefore, reduce the chance of evolutionary rescue for slow-growing tumors.</p><p>There are still some limitations to our models. Specifically, our model operates under the assumption that target cells will be eradicated upon the formation of IS. However, further improvements to our model that consider the varying killing efficiencies of different IS variants may enhance its clinical relevance and overall performance. For IS formation and T cell motility pattern: our models only considered a few select factors that influence the formation of IS, which may not provide a full description of drug inhomogeneous efficacy across anatomical sites. Factors like the heterogeneous distribution of T and B cells, chemokines, and stromal structures could affect the T cell motility and functions in tissue environments, and including these factors may provide an unbiased evaluation of drug effect across tissues. We assumed Brownian motion in the model as a good first approximation of T cell movement. However, T cells often take other more physiologically relevant searching strategies closely associated with many stromal factors. Because of these stromal factors, the cell-cell encounter probabilities would differ across anatomical sites. For T cell activation: our models did not include intracellular signaling processes, which are critical for T activation and cytotoxicity. However, our data suggest that encounter and adhesion are more relevant to initial IS formation. To make more clinically relevant predictions, the models should consider these intracellular signaling events that drive T cell activation and cytotoxic effects. Of note, we did consider the T cell expansion dynamics in organs as an independent variable during treatment for the simulations in <xref ref-type="fig" rid="fig6">Figure 6</xref>. T cell expansion in our model is case-specific and time-varying. For model parameters: the majority of model parameters were obtained or derived from the literature, and we did not perform model optimization to get the optimal values of model parameters. The only parameter we manually optimized is the sensitive coefficient for cell-cell adhesion in the base and in vivo model and the values were calibrated against the in vitro data. Implementing model optimization algorithms would improve the predictability of the models.</p><p>In conclusion, our study investigated the dynamics of IS formation under various conditions mimicking the heterogeneous nature of tumor microenvironments. To our knowledge, these theoretical models are the first to quantify the entire BiTE-induced IS formation process. The models reveal trajectories of tumor evolution through antigen escape across anatomical sites and suggest dosing regimens that could confer tumor control in light of treatment-induced disease evolution. This work has substantial implications for T cell-based immunotherapies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell lines</title><p>Jurkat (Clone E6-1) and Raji cells were obtained from ATCC and maintained in RPMI1640 supplemented with 10–20% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cell lines were routinely tested to avoid mycoplasma contamination. Cell lines have been authenticated by STR profiling and no mycoplasma contamination was detected.</p></sec><sec id="s4-2"><title>Cell sorting and antigen expression quantification</title><p>Cell populations with high (H), medium (M), and low (L) antigen expression were sorted based on natural expression levels, without any genetic engineering. PE-anti-CD3 and PE-anti-CD19 (BD Biosciences, San Jose, CA) were used as staining antibodies and BD FACSAria II was used to perform cell sorting. Surface expression of CD3 and CD19 was quantitatively determined by Quantum MESF beads (Bangs laboratories, Fishers, IN) and BD LSR II flow cytometry (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p></sec><sec id="s4-3"><title>Cell co-incubation and imaging flow cytometry</title><p>Effector cell (E, Jurkat), target cell (T, Raji), and anti-hCD19-CD3 BiTE (BioVision, Milpitas, CA) were well mixed and co-incubated in 1 mL medium at 37 °C. CD3 or CD19 expression, drug concentration, cell density, E:T ratio, and duration of co-incubation varied as initial setups. All samples were biological triplicates. After co-incubation, the effector cell, target cell, actin, and nucleus were stained by FITC-anti-CD7 (eBiosciences, San Diego, CA), PE-anti-CD20 (BD Biosciences, San Jose, CA), AF647-anti-phalloidin (Thermo Fisher, Waltham, MA) and DAPI, respectively. Staining for surface and intracellular markers was performed as described previously (<xref ref-type="bibr" rid="bib31">Liu et al., 2019</xref>). Samples were analyzed using Amnis ImageStream MKII (Luminex, Austin, TX). The frequency of IS was quantified using IDEAS (Luminex). The gating strategy is summarized in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p></sec><sec id="s4-4"><title>Cell co-incubation under shear stress</title><p>To mimic the shear stress in blood circulation, the effector cell, target cell, and BiTE were well mixed in a circular pipe (internal diameter: 1.6 mm) and co-cultured (37 °C) at a certain flow velocity driven by a roller pump (Masterflex, Vernon Hills, IL). Flow velocities were adjusted to produce varying wall shear stresses, equivalent to those in the vein (1–6 dyn/cm<sup>2</sup>), artery (10–24, dyn/cm<sup>2</sup>), and capillary (20–40 dyn/cm<sup>2</sup>) (<xref ref-type="bibr" rid="bib28">Kamiya et al., 1984</xref>; <xref ref-type="bibr" rid="bib36">Papaioannou and Stefanadis, 2005</xref>; <xref ref-type="bibr" rid="bib45">Sebastian and Dittrich, 2018</xref>). After co-culture, sample staining and analysis were the same as previously described.</p></sec><sec id="s4-5"><title>Modeling and simulation</title><sec id="s4-5-1"><title>Base model</title><p>Mechanistic agent-based models were developed to simulate IS formation dynamics in vitro and in vivo. We employed a sequential model-building strategy. First, we developed a model to capture IS formation dynamics within 1 hr, called the base model. The base model consisted of three modules at different dimensions: antibody-antigen binding (3D), cell-cell encounter, and cell-cell adhesion (2D) (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>).</p><p>Antibody-antigen binding to form binary complexes (BiTE-CD3 and BiTE-CD19) was considered a 3D process among free molecules. Rapid equilibrium was assumed. At specific total concentrations of CD3 (A), CD19 (B), and BiTE (Y) in the co-incubation system, the equilibrium concentrations of free antigens ([A] and [B]) and binary complex ([AY] and [YB]) (Appendix 1.1) were solved according to a model with two competing binding ligands (<xref ref-type="bibr" rid="bib59">Yan et al., 2012</xref>). Heterogeneous cell populations at equilibrium were generated by randomly assigning antigens and binary complexes to each individual cell (assign A and AY to the effector cell, B and YB to target cell). The distribution of assigned antigens on the cells were consistent with measured CD3 and CD19 expressions in respective cell lines (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>).</p><p>CD3 down-regulation on effector cells was also considered in our model (<xref ref-type="bibr" rid="bib30">Lanzavecchia et al., 1999</xref>; <xref ref-type="bibr" rid="bib43">San José et al., 2000</xref>; <xref ref-type="bibr" rid="bib47">Sousa and Carneiro, 2000</xref>; <xref ref-type="bibr" rid="bib51">Utzny et al., 2006</xref>; <xref ref-type="bibr" rid="bib52">Valitutti et al., 1995</xref>; <xref ref-type="bibr" rid="bib55">Viola et al., 1997</xref>). The rate of CD3 down-regulation was modeled as a function of surface binary complex abundance ([AY]’), which was described by an empirical equation that reached a steady state around 1 hr incubation, in line with the literature (Appendix 1.2). CD19 internalization was also introduced at a rate constant of 0.002 /min (<xref ref-type="bibr" rid="bib13">Du et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Ingle et al., 2008</xref>). Changes in surface antigen abundance ([A]’, [AY]’, and [YB]’) for each cell were updated every 60 s in the model.</p><p>Encounters between effector and target cells are an essential step for IS formation. We adopted an approximate equation to determine the encounter probability of one effector cell meeting at least one target cell within a specific time, which is a function of the number of target cells in the system (<xref ref-type="bibr" rid="bib6">Celli et al., 2012</xref>). We assumed that effector cells diffuse independently, moving in Brownian motion, while target cells were immotile. For simplicity, the IS and IS variants were considered as a singular moving cell entity when calculating the probability of encountering an additional free cell. Notably, spatial factors were considered in this encounter probability. The equations and parameters are provided in Appendix 1.3; the spatial coefficients for different encounter scenarios are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>. Encounter probabilities were re-calculated every 60 s in the model due to the changing number of free cells over time.</p><p>When an effector cell physically contacts a target cell, it may have a chance to adhere or diffuse away. Cell-cell adhesion is mediated by ternary complexes (AYB, bond) formed from binary complexes (AY or YB) and the availability of free antigens (B or A) on opposing cell surfaces (2D binding) (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>). We assumed that stable adhesion relied on generating sufficient AYB bonds within a short contact duration. Differential equations were used to simulate the number of AYB bonds. The relationship between adhesion probability and the bond number was described by a modified deterministic equation (Appendxi 1.4; <xref ref-type="bibr" rid="bib8">Chesla et al., 1998</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2010</xref>). A higher number of AYB bonds yielded a higher chance for engagements to result in an IS. The randomness arose from randomly assigned antigen expressions on both cells and contact duration (0.1–5 s). It is noteworthy that the ‘on’ and ‘off’ rate constants used in the equations are 2D kinetic constants on the cellular membrane, which were derived from 3D rate constants by a ‘single-step model’ (Appendxi 1.5; <xref ref-type="bibr" rid="bib3">Bell, 1978</xref>; <xref ref-type="bibr" rid="bib12">Dreier et al., 2002</xref>; <xref ref-type="bibr" rid="bib15">Faro et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Jansson, 2010</xref>).</p><p>In the base model (time scale ≤1 hr), each free cell had only one chance to encounter in each round (60 s). Cells that failed to encounter or adhere would remain free cells in the next round. Newly formed IS would have a chance to encounter an additional free cell to form an IS variant in the next round (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Only one free cell was allowed to be added at a time. IS variants of up to four cells were allowed in the model. The algorithm for the base model is provided in <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>. Other important assumptions in the base model include: (1) no cell proliferation within 1 hr; (2) no change in binding equilibrium for binary complex within 1 hr; (3) once formed, IS are not breakable; (4) target cells were assumed to be eradicated after IS formation, without distinguishing between typical IS and IS variants.</p></sec><sec id="s4-5-2"><title>In vitro model</title><p>Next, the in vitro model was developed by incorporating serial cell engagement into the base model (<xref ref-type="fig" rid="fig1">Figures 1b</xref> and <xref ref-type="fig" rid="fig5">5a</xref>). The duration of IS was assumed to be 150 min (<xref ref-type="bibr" rid="bib17">Fousek et al., 2021</xref>), and the detached effector cells from IS became free cells for additional IS formation. We made the following updates and assumptions to extend the time scale to 72 hr: (1) binding equilibrium for the binary complex was recalibrated every hour; (2) CD19 internalization was ignored; (3) CD3 down-regulation remained unchanged after 1 hr; (4) BiTE concentration remained constant; (5) target cell death rate is not included as target cells were assumed to be eradicated after IS formation.</p></sec><sec id="s4-5-3"><title>Clinical translation (in vivo model)</title><p>Lastly, we expanded the model to develop the in vivo model for simulating tumor-killing profiles in patients. Several additional modules, including multiple organ compartments and cell trafficking across organs, were defined in the in vivo model (<xref ref-type="fig" rid="fig1">Figures 1b</xref> and <xref ref-type="fig" rid="fig6">6a</xref>).</p><p>In the in vivo model, IS formation occurred within each organ-specific environment (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). BiTE concentrations and antigen expression (CD3 and CD19) in human T and B cells were estimated based on reported values (<xref ref-type="bibr" rid="bib18">Ginaldi et al., 1996</xref>; <xref ref-type="bibr" rid="bib19">Ginaldi et al., 1998</xref>; <xref ref-type="bibr" rid="bib21">Haso et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Jiang et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Ramakrishna et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Rosenthal et al., 2018</xref>). The patient-specific T and B cell densities at the organ level were derived based on the blood T and B cell numbers and the pre-defined ‘partition repertoire’, which reflected the relative cell abundance between blood and each organ (<xref ref-type="bibr" rid="bib20">Hall et al., 2012</xref>; <xref ref-type="bibr" rid="bib22">Hassan and El-Sheemy, 2004</xref>; <xref ref-type="bibr" rid="bib56">Westermann and Pabst, 1992</xref>).</p><p>The rate of B cell trafficking to blood (k<sub>traff, out</sub>) was set at 4.17% per hour, which represents the fraction of B cells trafficking through the blood during a day relative to the total B cell in the system, in line with clinical data (<xref ref-type="bibr" rid="bib56">Westermann and Pabst, 1992</xref>). Each hour, 4.17% of B cells in each organ were randomly released to the blood and then reassigned to a new organ according to the pre-defined ‘partition repertoire’ representing trafficking through the blood. Therefore, the rate of B cell trafficking to the organ (k<sub>traff, in</sub>) was assumed to be organ specific. T cell trafficking was not modeled, as T cell death was ignored. B cell turnover and changes in T cell densities and BiTE dose over time were allowed (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b and c</xref>). Similar to base and in vitro model, B cell death rate was not included as B cells were assumed to be eradicated after IS formation.</p><p>As the model output, blood B cell levels after treatment was derived from the residual B cells in organs based on the pre-defined ‘partition repertoire’.</p></sec></sec><sec id="s4-6"><title>Data source, software, and code availability</title><p>Publicly available clinical data (<xref ref-type="bibr" rid="bib2">Bargou et al., 2008</xref>; <xref ref-type="bibr" rid="bib29">Klinger et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Zhu et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Zhu et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Zugmaier et al., 2015</xref>) were digitized from the literature using WebPlot Digitizer. Simulation, plotting, and statistical analysis were implemented in R (3.6.0). The base model code can be found on GitHub at <ext-link ext-link-type="uri" xlink:href="https://github.com/zhoujw14/BiTE-Code">https://github.com/zhoujw14/BiTE-Code</ext-link>, (copy archived at <xref ref-type="bibr" rid="bib60">Zhou, 2022</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>A summary of model parameters and clinical trial information.</title><p>(a) Model parameters for the base model. (b) Patient-specific parameters for the in vivo model. (c) Clinical trial information in our simulation.</p></caption><media xlink:href="elife-83659-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83659-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The model code and source data are included in the GitHub <ext-link ext-link-type="uri" xlink:href="https://github.com/zhoujw14/BiTE-Code.git">https://github.com/zhoujw14/BiTE-Code.git</ext-link> (copy archived at <xref ref-type="bibr" rid="bib60">Zhou, 2022</xref>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Amgen Inc for kindly sharing blinatumomab to support our pilot study. National Institute of Health, R35GM119661.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldoss</surname><given-names>I</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Stiller</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Palmer</surname><given-names>J</given-names></name><name><surname>O’Donnell</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>AS</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Forman</surname><given-names>S</given-names></name><name><surname>Pullarkat</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Correlates of resistance and relapse during Blinatumomab therapy for Relapsed/refractory acute Lymphoblastic leukemia</article-title><source>American Journal of Hematology</source><volume>92</volume><fpage>858</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1002/ajh.24783</pub-id><pub-id pub-id-type="pmid">28494518</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bargou</surname><given-names>R</given-names></name><name><surname>Leo</surname><given-names>E</given-names></name><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Goebeler</surname><given-names>M</given-names></name><name><surname>Knop</surname><given-names>S</given-names></name><name><surname>Noppeney</surname><given-names>R</given-names></name><name><surname>Viardot</surname><given-names>A</given-names></name><name><surname>Hess</surname><given-names>G</given-names></name><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Brandl</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Kirchinger</surname><given-names>P</given-names></name><name><surname>Klappers</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Riethmüller</surname><given-names>G</given-names></name><name><surname>Reinhardt</surname><given-names>C</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Kufer</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tumor regression in cancer patients by very low doses of a T cell-engaging antibody</article-title><source>Science</source><volume>321</volume><fpage>974</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1126/science.1158545</pub-id><pub-id pub-id-type="pmid">18703743</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>GI</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Models for the specific adhesion of cells to cells</article-title><source>Science</source><volume>200</volume><fpage>618</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1126/science.347575</pub-id><pub-id pub-id-type="pmid">347575</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betts</surname><given-names>A</given-names></name><name><surname>Haddish-Berhane</surname><given-names>N</given-names></name><name><surname>Shah</surname><given-names>DK</given-names></name><name><surname>van der Graaf</surname><given-names>PH</given-names></name><name><surname>Barletta</surname><given-names>F</given-names></name><name><surname>King</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Kamperschroer</surname><given-names>C</given-names></name><name><surname>Root</surname><given-names>A</given-names></name><name><surname>Hooper</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Translational quantitative systems pharmacology model for Cd3 Bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-Cadherin LP DART</article-title><source>The AAPS Journal</source><volume>21</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1208/s12248-019-0332-z</pub-id><pub-id pub-id-type="pmid">31119428</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braig</surname><given-names>F</given-names></name><name><surname>Brandt</surname><given-names>A</given-names></name><name><surname>Goebeler</surname><given-names>M</given-names></name><name><surname>Tony</surname><given-names>H-P</given-names></name><name><surname>Kurze</surname><given-names>A-K</given-names></name><name><surname>Nollau</surname><given-names>P</given-names></name><name><surname>Bumm</surname><given-names>T</given-names></name><name><surname>Böttcher</surname><given-names>S</given-names></name><name><surname>Bargou</surname><given-names>RC</given-names></name><name><surname>Binder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resistance to anti-Cd19/Cd3 bite in acute Lymphoblastic leukemia may be mediated by disrupted Cd19 membrane trafficking</article-title><source>Blood</source><volume>129</volume><fpage>100</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-05-718395</pub-id><pub-id pub-id-type="pmid">27784674</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>AJ</given-names></name><name><surname>Molina-Paris</surname><given-names>C</given-names></name><name><surname>Lythe</surname><given-names>G</given-names></name><name><surname>Bousso</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>How many Dendritic cells are required to initiate a T-cell response?</article-title><source>Blood</source><volume>120</volume><fpage>3945</fpage><lpage>3948</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-01-408260</pub-id><pub-id pub-id-type="pmid">22995897</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Narula</surname><given-names>J</given-names></name><name><surname>Pascua</surname><given-names>E</given-names></name><name><surname>Ni</surname><given-names>I</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Chu</surname><given-names>MLH</given-names></name><name><surname>Pham</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Lindquist</surname><given-names>KC</given-names></name><name><surname>Doonan</surname><given-names>PJ</given-names></name><name><surname>Van Blarcom</surname><given-names>T</given-names></name><name><surname>Yeung</surname><given-names>YA</given-names></name><name><surname>Chaparro-Riggers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein Therapeutics</article-title><source>MAbs</source><volume>13</volume><elocation-id>1871171</elocation-id><pub-id pub-id-type="doi">10.1080/19420862.2020.1871171</pub-id><pub-id pub-id-type="pmid">33557687</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesla</surname><given-names>SE</given-names></name><name><surname>Selvaraj</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Measuring two-dimensional receptor-ligand binding Kinetics by Micropipette</article-title><source>Biophysical Journal</source><volume>75</volume><fpage>1553</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(98)74074-3</pub-id><pub-id pub-id-type="pmid">9726957</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>K</given-names></name><name><surname>Castello</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Balasubramani</surname><given-names>A</given-names></name><name><surname>Boudreau</surname><given-names>A</given-names></name><name><surname>Davison</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>KE</given-names></name><name><surname>Pham</surname><given-names>D</given-names></name><name><surname>Sankaran</surname><given-names>P</given-names></name><name><surname>Ugamraj</surname><given-names>HS</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Kwek</surname><given-names>S</given-names></name><name><surname>Starzinski</surname><given-names>A</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>van Schooten</surname><given-names>W</given-names></name><name><surname>Schellenberger</surname><given-names>U</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Trinklein</surname><given-names>ND</given-names></name><name><surname>Buelow</surname><given-names>R</given-names></name><name><surname>Buelow</surname><given-names>B</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Dalvi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Attenuating Cd3 affinity in a Psmaxcd3 Bispecific antibody enables killing of prostate tumor cells with reduced cytokine release</article-title><source>Journal for Immunotherapy of Cancer</source><volume>9</volume><elocation-id>e002488</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2021-002488</pub-id><pub-id pub-id-type="pmid">34088740</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delon</surname><given-names>J</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Information transfer at the immunological Synapse</article-title><source>Current Biology</source><volume>10</volume><fpage>R923</fpage><lpage>R933</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(00)00870-8</pub-id><pub-id pub-id-type="pmid">11137031</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglass</surname><given-names>EF</given-names></name><name><surname>Miller</surname><given-names>CJ</given-names></name><name><surname>Sparer</surname><given-names>G</given-names></name><name><surname>Shapiro</surname><given-names>H</given-names></name><name><surname>Spiegel</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A comprehensive mathematical model for three-body binding Equilibria</article-title><source>Journal of the American Chemical Society</source><volume>135</volume><fpage>6092</fpage><lpage>6099</lpage><pub-id pub-id-type="doi">10.1021/ja311795d</pub-id><pub-id pub-id-type="pmid">23544844</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreier</surname><given-names>T</given-names></name><name><surname>Lorenczewski</surname><given-names>G</given-names></name><name><surname>Brandl</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Syring</surname><given-names>U</given-names></name><name><surname>Hanakam</surname><given-names>F</given-names></name><name><surname>Kufer</surname><given-names>P</given-names></name><name><surname>Riethmuller</surname><given-names>G</given-names></name><name><surname>Bargou</surname><given-names>R</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Extremely potent, rapid and Costimulation-independent cytotoxic T-cell response against lymphoma cells Catalyzed by a single-chain Bispecific antibody</article-title><source>International Journal of Cancer</source><volume>100</volume><fpage>690</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1002/ijc.10557</pub-id><pub-id pub-id-type="pmid">12209608</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Beers</surname><given-names>R</given-names></name><name><surname>Fitzgerald</surname><given-names>DJ</given-names></name><name><surname>Pastan</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Differential cellular Internalization of anti-Cd19 and -Cd22 Immunotoxins results in different cytotoxic activity</article-title><source>Cancer Research</source><volume>68</volume><fpage>6300</fpage><lpage>6305</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0461</pub-id><pub-id pub-id-type="pmid">18676854</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dustin</surname><given-names>ML</given-names></name><name><surname>Cooper</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The immunological Synapse and the actin cytoskeleton: molecular hardware for T cell signaling</article-title><source>Nature Immunology</source><volume>1</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/76877</pub-id><pub-id pub-id-type="pmid">10881170</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faro</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Molina-París</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A unifying mathematical framework for experimental TCR-pMHC kinetic constants</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>46741</elocation-id><pub-id pub-id-type="doi">10.1038/srep46741</pub-id><pub-id pub-id-type="pmid">28443634</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finetti</surname><given-names>F</given-names></name><name><surname>Baldari</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The immunological Synapse as a pharmacological target</article-title><source>Pharmacological Research</source><volume>134</volume><fpage>118</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.06.009</pub-id><pub-id pub-id-type="pmid">29898412</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fousek</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>SK</given-names></name><name><surname>George</surname><given-names>A</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Byrd</surname><given-names>TT</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Luong</surname><given-names>A</given-names></name><name><surname>Martínez-Paniagua</surname><given-names>MA</given-names></name><name><surname>Sanber</surname><given-names>K</given-names></name><name><surname>Navai</surname><given-names>SA</given-names></name><name><surname>Gad</surname><given-names>AZ</given-names></name><name><surname>Salsman</surname><given-names>VS</given-names></name><name><surname>Mathew</surname><given-names>PR</given-names></name><name><surname>Kim</surname><given-names>HN</given-names></name><name><surname>Wagner</surname><given-names>DL</given-names></name><name><surname>Brunetti</surname><given-names>L</given-names></name><name><surname>Jang</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>ML</given-names></name><name><surname>Varadarajan</surname><given-names>N</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Heisterkamp</surname><given-names>N</given-names></name><name><surname>Abdel-Azim</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CAR T-cells that target acute B-lineage leukemia irrespective of Cd19 expression</article-title><source>Leukemia</source><volume>35</volume><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-0792-2</pub-id><pub-id pub-id-type="pmid">32205861</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginaldi</surname><given-names>L</given-names></name><name><surname>Matutes</surname><given-names>E</given-names></name><name><surname>Farahat</surname><given-names>N</given-names></name><name><surname>De Martinis</surname><given-names>M</given-names></name><name><surname>Morilla</surname><given-names>R</given-names></name><name><surname>Catovsky</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Differential expression of Cd3 and Cd7 in T-cell malignancies: a quantitative study by flow Cytometry</article-title><source>British Journal of Haematology</source><volume>93</volume><fpage>921</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.1996.d01-1720.x</pub-id><pub-id pub-id-type="pmid">8703826</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginaldi</surname><given-names>L</given-names></name><name><surname>De Martinis</surname><given-names>M</given-names></name><name><surname>Matutes</surname><given-names>E</given-names></name><name><surname>Farahat</surname><given-names>N</given-names></name><name><surname>Morilla</surname><given-names>R</given-names></name><name><surname>Catovsky</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Levels of expression of Cd19 and Cd20 in chronic B cell Leukaemias</article-title><source>Journal of Clinical Pathology</source><volume>51</volume><fpage>364</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1136/jcp.51.5.364</pub-id><pub-id pub-id-type="pmid">9708202</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Lueshen</surname><given-names>E</given-names></name><name><surname>Mošat’</surname><given-names>A</given-names></name><name><surname>Linninger</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Interspecies Scaling in pharmacokinetics: a novel whole-body Physiologically based modeling framework to discover drug Biodistribution mechanisms in vivo</article-title><source>Journal of Pharmaceutical Sciences</source><volume>101</volume><fpage>1221</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1002/jps.22811</pub-id><pub-id pub-id-type="pmid">22105643</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haso</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>DW</given-names></name><name><surname>Shah</surname><given-names>NN</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>CM</given-names></name><name><surname>Pastan</surname><given-names>IH</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>FitzGerald</surname><given-names>DJ</given-names></name><name><surname>Barrett</surname><given-names>DM</given-names></name><name><surname>Wayne</surname><given-names>AS</given-names></name><name><surname>Mackall</surname><given-names>CL</given-names></name><name><surname>Orentas</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Anti-Cd22-Chimeric antigen receptors targeting B-cell precursor acute Lymphoblastic leukemia</article-title><source>Blood</source><volume>121</volume><fpage>1165</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-06-438002</pub-id><pub-id pub-id-type="pmid">23243285</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>HT</given-names></name><name><surname>El-Sheemy</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Adult bone-marrow stem cells and their potential in medicine</article-title><source>Journal of the Royal Society of Medicine</source><volume>97</volume><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1177/0141076809701003</pub-id><pub-id pub-id-type="pmid">15459256</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zarnitsyna</surname><given-names>VI</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Edwards</surname><given-names>LJ</given-names></name><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>Evavold</surname><given-names>BD</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The Kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness</article-title><source>Nature</source><volume>464</volume><fpage>932</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1038/nature08944</pub-id><pub-id pub-id-type="pmid">20357766</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingle</surname><given-names>GS</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Elliott</surname><given-names>JM</given-names></name><name><surname>Chang</surname><given-names>WS</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Stephan</surname><given-names>J-P</given-names></name><name><surname>Scales</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>High Cd21 expression inhibits Internalization of anti-Cd19 antibodies and cytotoxicity of an anti-Cd19-drug conjugate</article-title><source>British Journal of Haematology</source><volume>140</volume><fpage>46</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2007.06883.x</pub-id><pub-id pub-id-type="pmid">17991300</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A mathematical framework for analyzing T cell receptor scanning of peptides</article-title><source>Biophysical Journal</source><volume>99</volume><fpage>2717</fpage><lpage>2725</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2010.08.024</pub-id><pub-id pub-id-type="pmid">21044568</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Carpenter</surname><given-names>TJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>HM</given-names></name><name><surname>Heald</surname><given-names>DL</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Development of a target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting Bispecific agents</article-title><source>MAbs</source><volume>10</volume><fpage>876</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1080/19420862.2018.1480299</pub-id><pub-id pub-id-type="pmid">29985776</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Jaiprasart</surname><given-names>P</given-names></name><name><surname>Carpenter</surname><given-names>TJ</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Development of a minimal Physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting Bispecific agents in humans</article-title><source>European Journal of Pharmaceutical Sciences</source><volume>146</volume><elocation-id>105260</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105260</pub-id><pub-id pub-id-type="pmid">32058058</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiya</surname><given-names>A</given-names></name><name><surname>Bukhari</surname><given-names>R</given-names></name><name><surname>Togawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Adaptive regulation of Wall shear stress optimizing vascular tree function</article-title><source>Bulletin of Mathematical Biology</source><volume>46</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/BF02463726</pub-id><pub-id pub-id-type="pmid">6713148</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Brandl</surname><given-names>C</given-names></name><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>Hijazi</surname><given-names>Y</given-names></name><name><surname>Bargou</surname><given-names>RC</given-names></name><name><surname>Topp</surname><given-names>MS</given-names></name><name><surname>Gökbuget</surname><given-names>N</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><name><surname>Goebeler</surname><given-names>M</given-names></name><name><surname>Viardot</surname><given-names>A</given-names></name><name><surname>Stelljes</surname><given-names>M</given-names></name><name><surname>Brüggemann</surname><given-names>M</given-names></name><name><surname>Hoelzer</surname><given-names>D</given-names></name><name><surname>Degenhard</surname><given-names>E</given-names></name><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Kufer</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Immunopharmacologic response of patients with B-lineage acute Lymphoblastic leukemia to continuous infusion of T cell-engaging Cd19/Cd3-Bispecific bite antibody Blinatumomab</article-title><source>Blood</source><volume>119</volume><fpage>6226</fpage><lpage>6233</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-01-400515</pub-id><pub-id pub-id-type="pmid">22592608</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Iezzi</surname><given-names>G</given-names></name><name><surname>Viola</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>From TCR engagement to T cell activation: a kinetic view of T cell behavior</article-title><source>Cell</source><volume>96</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)80952-6</pub-id><pub-id pub-id-type="pmid">9989490</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>MA</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamic Metrics-based biomarkers to predict responders to anti-PD-1 Immunotherapy</article-title><source>British Journal of Cancer</source><volume>120</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/s41416-018-0363-8</pub-id><pub-id pub-id-type="pmid">30587849</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>Mergen</surname><given-names>N</given-names></name><name><surname>Bader</surname><given-names>P</given-names></name><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Schlegel</surname><given-names>PG</given-names></name><name><surname>Bourquin</surname><given-names>JP</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name><name><surname>Brethon</surname><given-names>B</given-names></name><name><surname>Rössig</surname><given-names>C</given-names></name><name><surname>Kormany</surname><given-names>WN</given-names></name><name><surname>Viswagnachar</surname><given-names>P</given-names></name><name><surname>Chen-Santel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Blinatumomab in pediatric Relapsed/refractory B-cell acute Lymphoblastic leukemia: RIALTO expanded access study final analysis</article-title><source>Blood Advances</source><volume>6</volume><fpage>1004</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2021005579</pub-id><pub-id pub-id-type="pmid">34979020</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mejstríková</surname><given-names>E</given-names></name><name><surname>Hrusak</surname><given-names>O</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Whitlock</surname><given-names>JA</given-names></name><name><surname>Brethon</surname><given-names>B</given-names></name><name><surname>Trippett</surname><given-names>TM</given-names></name><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>Gore</surname><given-names>L</given-names></name><name><surname>von Stackelberg</surname><given-names>A</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cd19-negative relapse of pediatric B-cell precursor acute Lymphoblastic leukemia following Blinatumomab treatment</article-title><source>Blood Cancer Journal</source><volume>7</volume><elocation-id>659</elocation-id><pub-id pub-id-type="doi">10.1038/s41408-017-0023-x</pub-id><pub-id pub-id-type="pmid">29259173</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MJ</given-names></name><name><surname>Wei</surname><given-names>SH</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Autonomous T cell trafficking examined in vivo with Intravital two-photon microscopy</article-title><source>PNAS</source><volume>100</volume><fpage>2604</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1073/pnas.2628040100</pub-id><pub-id pub-id-type="pmid">12601158</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Kufer</surname><given-names>P</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Bargou</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Blinatumomab: a historical perspective</article-title><source>Pharmacology &amp; Therapeutics</source><volume>136</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.07.013</pub-id><pub-id pub-id-type="pmid">22940266</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaioannou</surname><given-names>TG</given-names></name><name><surname>Stefanadis</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Vascular wall shear stress: basic principles and methods</article-title><source>Hellenic Journal of Cardiology</source><volume>46</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15807389</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>V</given-names></name><name><surname>Muralidharan</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Bagashev</surname><given-names>A</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Rosenthal</surname><given-names>J</given-names></name><name><surname>Van Arnam</surname><given-names>J</given-names></name><name><surname>Melenhorst</surname><given-names>JJ</given-names></name><name><surname>Mohan</surname><given-names>D</given-names></name><name><surname>DiNofia</surname><given-names>AM</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Cherian</surname><given-names>S</given-names></name><name><surname>Fromm</surname><given-names>JR</given-names></name><name><surname>Wertheim</surname><given-names>G</given-names></name><name><surname>Thomas-Tikhonenko</surname><given-names>A</given-names></name><name><surname>Paessler</surname><given-names>M</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Luning Prak</surname><given-names>ET</given-names></name><name><surname>Bhoj</surname><given-names>VG</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Maude</surname><given-names>SL</given-names></name><name><surname>Rheingold</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CAR T-cell therapy is effective for Cd19-dim B-Lymphoblastic leukemia but is impacted by prior Blinatumomab therapy</article-title><source>Blood Advances</source><volume>3</volume><fpage>3539</fpage><lpage>3549</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000692</pub-id><pub-id pub-id-type="pmid">31738832</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishna</surname><given-names>S</given-names></name><name><surname>Highfill</surname><given-names>SL</given-names></name><name><surname>Walsh</surname><given-names>Z</given-names></name><name><surname>Nguyen</surname><given-names>SM</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Shern</surname><given-names>JF</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Kraft</surname><given-names>IL</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>CM</given-names></name><name><surname>Hwang</surname><given-names>JD</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Dimitrov</surname><given-names>D</given-names></name><name><surname>Shah</surname><given-names>NN</given-names></name><name><surname>Fry</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Modulation of target antigen density improves CAR T-cell Functionality and persistence</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>5329</fpage><lpage>5341</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-3784</pub-id><pub-id pub-id-type="pmid">31110075</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roda-Navarro</surname><given-names>P</given-names></name><name><surname>Álvarez-Vallina</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Understanding the spatial Topology of artificial immunological synapses assembled in T cell-redirecting strategies: A major issue in cancer Immunotherapy</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>7</volume><elocation-id>370</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2019.00370</pub-id><pub-id pub-id-type="pmid">31998721</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogala</surname><given-names>B</given-names></name><name><surname>Freyer</surname><given-names>CW</given-names></name><name><surname>Ontiveros</surname><given-names>EP</given-names></name><name><surname>Griffiths</surname><given-names>EA</given-names></name><name><surname>Wang</surname><given-names>ES</given-names></name><name><surname>Wetzler</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies</article-title><source>Expert Opinion on Biological Therapy</source><volume>15</volume><fpage>895</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1517/14712598.2015.1041912</pub-id><pub-id pub-id-type="pmid">25985814</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>J</given-names></name><name><surname>Naqvi</surname><given-names>AS</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Wertheim</surname><given-names>G</given-names></name><name><surname>Paessler</surname><given-names>M</given-names></name><name><surname>Thomas-Tikhonenko</surname><given-names>A</given-names></name><name><surname>Rheingold</surname><given-names>SR</given-names></name><name><surname>Pillai</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Heterogeneity of surface Cd19 and Cd22 expression in B Lymphoblastic leukemia</article-title><source>American Journal of Hematology</source><volume>93</volume><fpage>E352</fpage><lpage>E355</lpage><pub-id pub-id-type="doi">10.1002/ajh.25235</pub-id><pub-id pub-id-type="pmid">30058145</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samur</surname><given-names>MK</given-names></name><name><surname>Fulciniti</surname><given-names>M</given-names></name><name><surname>Aktas Samur</surname><given-names>A</given-names></name><name><surname>Bazarbachi</surname><given-names>AH</given-names></name><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Prabhala</surname><given-names>R</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Sperling</surname><given-names>AS</given-names></name><name><surname>Campbell</surname><given-names>T</given-names></name><name><surname>Petrocca</surname><given-names>F</given-names></name><name><surname>Hege</surname><given-names>K</given-names></name><name><surname>Kaiser</surname><given-names>S</given-names></name><name><surname>Loiseau</surname><given-names>HA</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>868</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21177-5</pub-id><pub-id pub-id-type="pmid">33558511</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San José</surname><given-names>E</given-names></name><name><surname>Borroto</surname><given-names>A</given-names></name><name><surname>Niedergang</surname><given-names>F</given-names></name><name><surname>Alcover</surname><given-names>A</given-names></name><name><surname>Alarcón</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Triggering the TCR complex causes the downregulation of Nonengaged receptors by a signal Transduction-dependent mechanism</article-title><source>Immunity</source><volume>12</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)80169-7</pub-id><pub-id pub-id-type="pmid">10714682</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schropp</surname><given-names>J</given-names></name><name><surname>Khot</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>DK</given-names></name><name><surname>Koch</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Target-mediated drug disposition model for Bispecific antibodies: properties, approximation, and optimal dosing strategy</article-title><source>CPT</source><volume>8</volume><fpage>177</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1002/psp4.12369</pub-id><pub-id pub-id-type="pmid">30480383</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebastian</surname><given-names>B</given-names></name><name><surname>Dittrich</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Microfluidics to Mimic blood flow in health and disease</article-title><source>Annual Review of Fluid Mechanics</source><volume>50</volume><fpage>483</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1146/annurev-fluid-010816-060246</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanistic prediction of first-in-human dose for Bispecific Cd3/Epcam T-cell Engager antibody M701, using an integrated PK/PD modeling method</article-title><source>European Journal of Pharmaceutical Sciences</source><volume>158</volume><elocation-id>105584</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105584</pub-id><pub-id pub-id-type="pmid">33039565</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>J</given-names></name><name><surname>Carneiro</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A mathematical analysis of TCR serial triggering and down-regulation</article-title><source>European Journal of Immunology</source><volume>30</volume><fpage>3219</fpage><lpage>3227</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(200011)30:11&lt;3219::AID-IMMU3219&gt;3.0.CO;2-7</pub-id><pub-id pub-id-type="pmid">11093137</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Lum</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bispecific antibody based Therapeutics: strengths and challenges</article-title><source>Blood Reviews</source><volume>32</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.blre.2018.02.004</pub-id><pub-id pub-id-type="pmid">29482895</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topp</surname><given-names>MS</given-names></name><name><surname>Gökbuget</surname><given-names>N</given-names></name><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>Klappers</surname><given-names>P</given-names></name><name><surname>Stelljes</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><name><surname>Viardot</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>R</given-names></name><name><surname>Diedrich</surname><given-names>H</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Reichle</surname><given-names>A</given-names></name><name><surname>Horst</surname><given-names>HA</given-names></name><name><surname>Brüggemann</surname><given-names>M</given-names></name><name><surname>Wessiepe</surname><given-names>D</given-names></name><name><surname>Holland</surname><given-names>C</given-names></name><name><surname>Alekar</surname><given-names>S</given-names></name><name><surname>Mergen</surname><given-names>N</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Hoelzer</surname><given-names>D</given-names></name><name><surname>Bargou</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Phase II trial of the anti-Cd19 Bispecific T cell-Engager Blinatumomab shows hematologic and molecular remissions in patients with Relapsed or refractory B-precursor acute Lymphoblastic leukemia</article-title><source>Journal of Clinical Oncology</source><volume>32</volume><fpage>4134</fpage><lpage>4140</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.56.3247</pub-id><pub-id pub-id-type="pmid">25385737</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topp</surname><given-names>MS</given-names></name><name><surname>Gökbuget</surname><given-names>N</given-names></name><name><surname>Stein</surname><given-names>AS</given-names></name><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>O’Brien</surname><given-names>S</given-names></name><name><surname>Bargou</surname><given-names>RC</given-names></name><name><surname>Dombret</surname><given-names>H</given-names></name><name><surname>Fielding</surname><given-names>AK</given-names></name><name><surname>Heffner</surname><given-names>L</given-names></name><name><surname>Larson</surname><given-names>RA</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><name><surname>Foà</surname><given-names>R</given-names></name><name><surname>Litzow</surname><given-names>M</given-names></name><name><surname>Ribera</surname><given-names>JM</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Schiller</surname><given-names>G</given-names></name><name><surname>Brüggemann</surname><given-names>M</given-names></name><name><surname>Horst</surname><given-names>HA</given-names></name><name><surname>Holland</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>C</given-names></name><name><surname>Maniar</surname><given-names>T</given-names></name><name><surname>Huber</surname><given-names>B</given-names></name><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Forman</surname><given-names>SJ</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Safety and activity of Blinatumomab for adult patients with Relapsed or refractory B-precursor acute Lymphoblastic leukaemia: a Multicentre, single-arm, phase 2 study</article-title><source>The Lancet. Oncology</source><volume>16</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)71170-2</pub-id><pub-id pub-id-type="pmid">25524800</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzny</surname><given-names>C</given-names></name><name><surname>Coombs</surname><given-names>D</given-names></name><name><surname>Müller</surname><given-names>S</given-names></name><name><surname>Valitutti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Analysis of peptide/MHC-induced TCR downregulation: Deciphering the triggering Kinetics</article-title><source>Cell Biochemistry and Biophysics</source><volume>46</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1385/CBB:46:2:101</pub-id><pub-id pub-id-type="pmid">17012752</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valitutti</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>S</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Padovan</surname><given-names>E</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Serial triggering of many T-cell receptors by a few peptide-MHC complexes</article-title><source>Nature</source><volume>375</volume><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/375148a0</pub-id><pub-id pub-id-type="pmid">7753171</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van De Vyver</surname><given-names>AJ</given-names></name><name><surname>Weinzierl</surname><given-names>T</given-names></name><name><surname>Eigenmann</surname><given-names>MJ</given-names></name><name><surname>Frances</surname><given-names>N</given-names></name><name><surname>Herter</surname><given-names>S</given-names></name><name><surname>Buser</surname><given-names>RB</given-names></name><name><surname>Somandin</surname><given-names>J</given-names></name><name><surname>Diggelmann</surname><given-names>S</given-names></name><name><surname>Limani</surname><given-names>F</given-names></name><name><surname>Lehr</surname><given-names>T</given-names></name><name><surname>Bacac</surname><given-names>M</given-names></name><name><surname>Walz</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Predicting tumor killing and T-cell activation by T-cell Bispecific antibodies as a function of target expression: combining <italic>in Vitro</italic> experiments with systems modeling</article-title><source>Molecular Cancer Therapeutics</source><volume>20</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-20-0269</pub-id><pub-id pub-id-type="pmid">33298591</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viardot</surname><given-names>A</given-names></name><name><surname>Bargou</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bispecific antibodies in haematological malignancies</article-title><source>Cancer Treatment Reviews</source><volume>65</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2018.04.002</pub-id><pub-id pub-id-type="pmid">29635163</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viola</surname><given-names>A</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Tuosto</surname><given-names>L</given-names></name><name><surname>Linkert</surname><given-names>S</given-names></name><name><surname>Acuto</surname><given-names>O</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Quantitative contribution of Cd4 and Cd8 to T cell antigen receptor serial triggering</article-title><source>The Journal of Experimental Medicine</source><volume>186</volume><fpage>1775</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1084/jem.186.10.1775</pub-id><pub-id pub-id-type="pmid">9362538</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermann</surname><given-names>J</given-names></name><name><surname>Pabst</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Distribution of lymphocyte Subsets and natural killer cells in the human body</article-title><source>The Clinical Investigator</source><volume>70</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1007/BF00184787</pub-id><pub-id pub-id-type="pmid">1392422</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Hsu</surname><given-names>YH</given-names></name><name><surname>Jang</surname><given-names>JH</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Dotti</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immunological Synapse predicts effectiveness of Chimeric antigen receptor cells</article-title><source>Molecular Therapy</source><volume>29</volume><fpage>1349</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.01.025</pub-id><pub-id pub-id-type="pmid">33592166</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanisms of relapse after Cd19 CAR T-cell therapy for acute Lymphoblastic leukemia and its prevention and treatment strategies</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2664</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02664</pub-id><pub-id pub-id-type="pmid">31798590</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Krzyzanski</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor</article-title><source>Journal of Pharmacokinetics and Pharmacodynamics</source><volume>39</volume><fpage>543</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1007/s10928-012-9267-z</pub-id><pub-id pub-id-type="pmid">22926955</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Bite-code</data-title><version designator="swh:1:rev:fe91100494399cdaa05694bed66d1d501f610ba2">swh:1:rev:fe91100494399cdaa05694bed66d1d501f610ba2</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:c516e7546f4b483dc809baf8eb459a8d2990009f;origin=https://github.com/zhoujw14/BiTE-Code;visit=swh:1:snp:356eea7ca45a86cf992b2b094bd50924a9c03eae;anchor=swh:1:rev:fe91100494399cdaa05694bed66d1d501f610ba2">https://archive.softwareheritage.org/swh:1:dir:c516e7546f4b483dc809baf8eb459a8d2990009f;origin=https://github.com/zhoujw14/BiTE-Code;visit=swh:1:snp:356eea7ca45a86cf992b2b094bd50924a9c03eae;anchor=swh:1:rev:fe91100494399cdaa05694bed66d1d501f610ba2</ext-link></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Brandl</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Doshi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Blinatumomab, a Bispecific T-cell Engager (bite) for CD-19 targeted cancer Immunotherapy: clinical pharmacology and its implications</article-title><source>Clinical Pharmacokinetics</source><volume>55</volume><fpage>1271</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1007/s40262-016-0405-4</pub-id><pub-id pub-id-type="pmid">27209293</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Kratzer</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Holland</surname><given-names>C</given-names></name><name><surname>Brandl</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Doshi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Blinatumomab pharmacodynamics and exposure-response relationships in Relapsed/refractory acute Lymphoblastic leukemia</article-title><source>Journal of Clinical Pharmacology</source><volume>58</volume><fpage>168</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1002/jcph.1006</pub-id><pub-id pub-id-type="pmid">28922466</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>Gökbuget</surname><given-names>N</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Viardot</surname><given-names>A</given-names></name><name><surname>Stelljes</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><name><surname>Horst</surname><given-names>HA</given-names></name><name><surname>Marks</surname><given-names>R</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Diedrich</surname><given-names>H</given-names></name><name><surname>Reichle</surname><given-names>A</given-names></name><name><surname>Brüggemann</surname><given-names>M</given-names></name><name><surname>Holland</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Bargou</surname><given-names>RC</given-names></name><name><surname>Topp</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Long-term survival and T-cell Kinetics in Relapsed/refractory ALL patients who achieved MRD response after Blinatumomab treatment</article-title><source>Blood</source><volume>126</volume><fpage>2578</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-06-649111</pub-id><pub-id pub-id-type="pmid">26480933</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>1.1 Antibody-antigen binding to form binary complex</title><p>The following schema described antibody-antigen binding to form binary complex. Two antigens (CD3 (A) and CD19 (B)) competing for the same BiTE antibody (Y) was considered as a 3D binding process among free molecules, which was supposed to reach the equilibrium rapidly after co-culture initiation.</p><fig id="app1scheme1" position="float"><label>Appendix 1—scheme 1.</label><caption><title>The schema for antibody-antigen binding to form the binary complex.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-app1-scheme1-v1.tif"/></fig><p>The equations to solve free antigen ([A] and [B]) and binary complex ([AY] and [YB]) concentration levels at equilibrium (<xref ref-type="bibr" rid="bib59">Yan et al., 2012</xref>):</p><list list-type="bullet"><list-item><p>Total concentrations:</p></list-item></list><p><disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><list list-type="bullet"><list-item><p>Dissociation constants:</p></list-item></list><p><disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><list list-type="bullet"><list-item><p>Get binary complex concentrations ([AY] and [YB]) from <xref ref-type="disp-formula" rid="equ1 equ1">equation (1) and (2)</xref>:</p></list-item></list><p><disp-formula id="equ3">  <label>(3)</label><mml:math id="m3"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:math></disp-formula></p><list list-type="bullet"><list-item><p>Where free antigen concentrations ([A] and [B]) at equilibrium (<xref ref-type="bibr" rid="bib59">Yan et al., 2012</xref>):</p></list-item></list><p><disp-formula id="equ4">  <label>(4)</label><mml:math id="m4"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>z</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>z</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle></mml:mstyle></mml:mrow></mml:math></disp-formula></p><list list-type="bullet"><list-item><p>Where z is the solution of a polynomial equation (for z solution see <xref ref-type="bibr" rid="bib59">Yan et al., 2012</xref>):</p></list-item></list><p><disp-formula id="equ5"><label>(5)</label><mml:math id="m5"><mml:mrow><mml:mi>I</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>≠</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>u</mml:mi><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo>:</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msup><mml:mi>z</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:msup><mml:mi>z</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mi>z</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></disp-formula><disp-formula id="equ6"><label>(6)</label><mml:math id="m6"><mml:mrow><mml:mi>z</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>z</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>z</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ7"><mml:math id="m7"><mml:mrow><mml:mtable columnalign="right left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi>H</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>,</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>b</mml:mi></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>c</mml:mi></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p></sec><sec sec-type="appendix" id="s9"><title>1.2 CD3 down-regulation and CD19 internalization within 1 h after binary-complex equilibrium</title><sec sec-type="appendix" id="s9-1"><title>A: CD3; B: CD19; Y: BiTE</title><p>CD3 down-regulation (empirical equations):<disp-formula id="equ8"><label>(7)</label><mml:math id="m8"><mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>0.1</mml:mn><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mo>]</mml:mo><mml:mi>`</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></disp-formula><disp-formula id="equ9"><label>(8)</label><mml:math id="m9"><mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>0.1</mml:mn><mml:mo>∙</mml:mo><mml:mo>[</mml:mo><mml:msup><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mo>]</mml:mo><mml:mi>`</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></disp-formula></p><p>where, for each effector cell, [AY]’ and [A]’ are assigned AY and A concentration on cell surface; [AY]’<sub>t</sub> and [A]’<sub>t</sub> are AY and A concentration on cell surface at time t; hill function: <italic>γ</italic>=0.9; h=0.7.</p><p>CD19 internalization:<disp-formula id="equ10"><label>(9)</label><mml:math id="m10"><mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula></p><p>where, for each target cell, [YB]’ is assigned YB concentration on cell surface; [YB]’<sub>t</sub> is the YB concentration on cell surface at time t; k<sub>int</sub> stands for internalization rate constant (0.002 min<sup>–1</sup>) (<xref ref-type="bibr" rid="bib13">Du et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Ingle et al., 2008</xref>)</p><p>The CD3 down-regulation over time at different blinatumomab concentrations was simulated as below.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Simulated CD3 down-regulation over time at different blinatumomab concentrations.</title><p>Initial setup: 2×106 total cells/mL, CD3 expression (L), CD19 expression (M), E:T ratio=1.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-app1-fig1-v1.tif"/></fig></sec></sec><sec sec-type="appendix" id="s10"><title>1.3 Equations and parameters for encounter probability</title><p>Encounter probability (<xref ref-type="bibr" rid="bib6">Celli et al., 2012</xref>):<disp-formula id="equ11"><label>(10)</label><mml:math id="m11"><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>T</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula><disp-formula id="equ12"><label>(11)</label><mml:math id="m12"><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>E</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mn>2</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ13"><label>(12)</label><mml:math id="m13"><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>T</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mn>2</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ14"><label>(13)</label><mml:math id="m14"><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>E</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>E</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mn>3</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ15"><label>(14)</label><mml:math id="m15"><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>E</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>T</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mn>3</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ16"><label>(15)</label><mml:math id="m16"><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>E</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mn>3</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ17"><label>(16)</label><mml:math id="m17"><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>T</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>T</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mn>3</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>T</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ18"><label>(17)</label><mml:math id="m18"><mml:mrow><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>α</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>g</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>b</mml:mi><mml:mi>y</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mfrac><mml:mn>1</mml:mn><mml:mi>α</mml:mi></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mn>3</mml:mn><mml:mi>D</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>where, Pe, encounter probability; E and T, cell number of free effector and target cells; t, time; f, spatial coefficients, the values were listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>; α, mean hitting rate; D, cell diffusivity in solution, 0.83 µm<sup>2</sup>·s<sup>–1</sup> (<xref ref-type="bibr" rid="bib34">Miller et al., 2003</xref>); b, distance between cell centers at encounter, 11 µm (radius: effector cell, 5 µm; target cell, 6 µm); R, radius of spherical co-culture system, 6200 µm (1 mL system).</p><p>The following schema depicted the spatial factor when a typical IS (ET) encounters an additional free target cell or effector cell. Based on imaging data, it was allowed a single effector cell to maximumly have 3 binding spots for target cells, whereas up to 4 effector cells for a single target cell. Dashed circles represent available spots for an additional effector or target cell binding to a typical IS (solid circles).</p><fig id="app1scheme2" position="float"><label>Appendix 1—scheme 2.</label><caption><title>Spatial factor when a typical immunological synapses (IS) (ET) encounters an additional free target cell or effector cell.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-app1-scheme2-v1.tif"/></fig><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>Graphical presentation of ternary complex (CD3-BiTE-CD19, bond) formation during cell-cell adhesion.</title><p>The bond is formed by binding between a binary complex and a free antigen (a), rather than two binary complexes (b) or two free antigens (c). Three steps of 2-D binding on membrane (d): diffusion, rotation, and molecular binding.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-app1-fig2-v1.tif"/></fig></sec><sec sec-type="appendix" id="s11"><title>1.4 Equations and parameters for ternary complex formation and adhesion probability</title><fig id="app1scheme3" position="float"><label>Appendix 1—scheme 3.</label><caption><title>The formation of ternary complex (AYB, bond).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-app1-scheme3-v1.tif"/></fig><p>The formation of ternary complex (AYB, bond) can be characterized as<disp-formula id="equ19"><label>(18)</label><mml:math id="m19"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula><disp-formula id="equ20"><label>(19)</label><mml:math id="m20"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula><disp-formula id="equ21"><label>(20)</label><mml:math id="m21"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula><disp-formula id="equ22"><label>(21)</label><mml:math id="m22"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula><disp-formula id="equ23"><label>(22)</label><mml:math id="m23"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula></p><p>Adhesion probability (<xref ref-type="bibr" rid="bib8">Chesla et al., 1998</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2010</xref>)<disp-formula id="equ24"><label>(23)</label><mml:math id="m24"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula><disp-formula id="equ25"><label>(24)</label><mml:math id="m25"><mml:mrow><mml:mi>P</mml:mi><mml:mi>a</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>τ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula></p><p>Where, <inline-formula><mml:math id="inf1"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> , effective rate constants for 2-D binding on membrane (see Appendix 1.5 and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>):</p><list list-type="simple"><list-item><p><inline-formula><mml:math id="inf2"><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:msup><mml:mrow><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, antigen density on cell surface;</p></list-item><list-item><p><inline-formula><mml:math id="inf3"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>τ</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula><sub>,</sub> bond number at time τ;</p></list-item><list-item><p><inline-formula><mml:math id="inf4"><mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, bond density at contact duration τ (randomly assigned from 0.1 to 5 s);</p></list-item><list-item><p><inline-formula><mml:math id="inf5"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, apparent contact area,~5 µm<sup>2</sup>;</p></list-item><list-item><p><inline-formula><mml:math id="inf6"><mml:mi>P</mml:mi><mml:mi>a</mml:mi></mml:math></inline-formula>, adhesion probability;</p></list-item><list-item><p>β, sensitive factor, 0.033 (for base and in-vitro model).</p></list-item></list></sec><sec sec-type="appendix" id="s12"><title>1.5 ‘Single-step model’ for 2-D binding on cell membrane</title><fig id="app1scheme4" position="float"><label>Appendix 1—scheme 4.</label><caption><title>‘Single-step model’ for 2-D binding on cell membrane.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-app1-scheme4-v1.tif"/></fig><p>Equations for effective kinetic constants for 2-D binding on cell membrane:</p><list list-type="bullet"><list-item><p>3-D binding in solution (<xref ref-type="bibr" rid="bib3">Bell, 1978</xref>; <xref ref-type="bibr" rid="bib15">Faro et al., 2017</xref>)</p></list-item></list><p><disp-formula id="equ26"><label>(25)</label><mml:math id="m26"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>4</mml:mn><mml:mi>π</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="2em"/><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="equ27"><label>(26)</label><mml:math id="m27"><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.04</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="2em"/><mml:mspace width="2em"/><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>4</mml:mn><mml:msup><mml:mi>π</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula><disp-formula id="equ28"><label>(27)</label><mml:math id="m28"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mspace width="2em"/><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Similar equations were applied for A+BY <inline-formula><mml:math id="inf7"><mml:mo>⇌</mml:mo></mml:math></inline-formula> AYB as well</p><list list-type="bullet"><list-item><p>2-D binding on membrane (<xref ref-type="bibr" rid="bib3">Bell, 1978</xref>; <xref ref-type="bibr" rid="bib15">Faro et al., 2017</xref>)</p></list-item></list><p><disp-formula id="equ29"><label>(28)</label><mml:math id="m29"><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="2em"/><mml:mspace width="2em"/><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="equ30"><label>(29)</label><mml:math id="m30"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.04</mml:mn><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>;</mml:mo><mml:mspace width="2em"/><mml:mspace width="2em"/><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>4</mml:mn><mml:msup><mml:mi>π</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ31"><label>(30)</label><mml:math id="m31"><mml:mrow><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mspace width="2em"/><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><list list-type="bullet"><list-item><p>Similar equations were applied for A+BY <inline-formula><mml:math id="inf8"><mml:mo>⇌</mml:mo></mml:math></inline-formula> AYB as well</p></list-item></list><p>Where, <inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, forward and reverse rate constants of antigen encounter;</p><list list-type="simple"><list-item><p><inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, forward and reverse rate constants of antigen rotation;</p></list-item><list-item><p><inline-formula><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, chemical association and dissociation rate constants;</p></list-item><list-item><p><inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, effective rate constants, see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>;</p></list-item><list-item><p><inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, diffusion constant in solution, <inline-formula><mml:math id="inf14"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>Y</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> , 50 µm<sup>2</sup>/s (<xref ref-type="bibr" rid="bib3">Bell, 1978</xref>);</p></list-item><list-item><p><inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, diffusion constant on membrane, <inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> = 0.01 µm<sup>2</sup>/s (<xref ref-type="bibr" rid="bib3">Bell, 1978</xref>);</p></list-item><list-item><p><inline-formula><mml:math id="inf17"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>Y</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, distance of reactants (AY and B), 5 nm (<xref ref-type="bibr" rid="bib25">Jansson, 2010</xref>).</p></list-item></list><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Algorithm for the base model.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-app1-fig3-v1.tif"/></fig></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83659.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.04.18.488626" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.18.488626"/></front-stub><body><p>This work provides an important finding, that aspects of clinical outcomes can be predicted by a random search to an immunological synapse-based computational model for T cells directed by specific engagers. It provides solid evidence based on in vitro synapse formation measurements using imaging flow cytometry. The work will be of interest to investigators in the still-expanding immunotherapy field, and also as an example of how biologic drugs interface with endogenous cellular resources in a patient.’</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83659.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Jiang</surname><given-names>Xiling</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.18.488626">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.04.18.488626v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Population Dynamics of Immunological Synapse Formation Induced by Bispecific T-cell Engagers Predict Clinical Pharmacodynamics and Treatment Resistance&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Michael L Dustin as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Aleksandra Walczak as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Xiling Jiang (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Cell adhesion molecules are regulated by TCR are not explicitly included in the model. Do the author feel that BITEs are not triggering these mechanisms or that their action is directly related to BiTE mediated interactions that are explicitly modelled such that the contributions of adhesion are included in the contributions of the BiTE interactions.</p><p>2. T cell movements in tissue is not a random walk, but is scaffolded by stromal cells and extracellular matrix to generate a variety of search strategies, which have been reported in the literature. Do any of the surprising results from the model potentially arise from known, non-Brownian aspects of T cell migration in tissues (or from aspects of cell adhesion in tissues that are not linear related to BiTE mediated interactions).</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors use Jurkat-Raji combination for imaging flow cytometry. Jurkat is likely to use the CD2-CD58 adhesion system to engage Raji and this could be investigated with antibodies to CD2 or CD58. It is not clear to me how the simple use of blinatumomab bridge formation can correctly model the adhesion process. I suspect this works because the CD2-CD58 system is likely to be a constant and the frequency of blinatumomab Bridges is controlling signaling that promoted CD2-CD58 interaction to mediate conjugate formation and observed actin polymerisation. So the modelling may be correct in predicting the bell shape, but would not hold up if the physical requirements for synapse formation were correctly modelled. So the inclusion of CD2-CD58 and other adhesion systems may not change some aspects of the models, but it would provide another escape route for the tumour- through CD58 loss rather than CD19 loss.</p><p>Understanding the competition between adhesion and motility in the tumour may be important to understand the dissociation process. So chemokinesis may be an important thing to consider that may different in different settings. Due to chemokine like CXCL12 and CCL19/21 it may be very strong in lymphoid tissues, but bone marrow and other tissues may have very different landscapes of chemokine and thus the drive to disengage from a target may be lower or higher.</p><p>In terms of search models, the actual movement pattern will depend upon the underlying stroma. In a lymph node this network allows for frequent turns and exploration of the 3D space, where in some tumours the stroma may be more oriented and may convey T cells toward or away from the tumour. In the CNS, Lévy flight was found to be more efficient than a random walk would have been. Can this complexity explain any situation where the model predictions didn't hold?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. What is the major purpose of modeling the immune synapse variants? Are they expected to have clinical significance (e.g., increase /decrease in efficacy, induce tumor antigen escape)?</p><p>2. In page 10 Figure 3, the incubation system was defined with X x 10E6 cells/mL, does this refer to total cell numbers (i.e., E + T cells), effector cells numbers or target cell numbers, please clarify in the figure legend for each respective experimental condition (e.g., Figure 3h and 3i, when you have different E:T ratios).</p><p>3. In page 10 Figure 3h, I would like recommend separation of effector cells and target cells, given that engagement of target cells is expected to be more clinically relevant.</p><p>4. In page 12 line 233, it was stated that &quot;IS formation was optimized when the E:T ratio was around 1&quot;. Given that a lot of in vitro studies a conducted using E:T ratio 5:1 or 10:1, do you think your simulation results can be used to modify the in vitro study experimental condition towards better outcome?</p><p>5. Page 15 Figure 5c and 5d, do you have any observed data to verify the model simulated reduction in CD19 expression level following blinatumomab treatment?</p><p>6. Page 15 Figure 5e and 5f, one major concern for me is that your model simulation suggested that the bispecific is more effective in spleen and bone marrow compared to that in bone marrow, which generally against the clinical observation (e.g., the expected efficacious dose of blinatumomab for Acute Lymphoblastic Leukemia [major site of action is bone marrow] and Non-Hodgkin's Lymphoma [major site of action is lymph node] are 15 ug/m2/day vs. 60 ug/m2/day, respectively), and animal data (e.g., MGD-011 showed much strong B cell depletion effect in bone marrow compared to that in spleen and lymph node, PMID: 27663593). This may be associated with the heterogenous distribution of T cells and B cells in the lymph node and spleen (https://www.google.com/url?sa=iandurl=https%3A%2F%2Fimmunox.ucsf.edu%2Fsites%2Fimmunox.ucsf.edu%2Ffiles%2Fpdf%2FMicro204_Anat_IR%2520v2018.pdfandpsig=AOvVaw0qOMQka3SNN7k762B84FYDandust=1670808103053000andsource=imagesandcd=vfeandved=0CBAQjhxqFwoTCLC0za2z8PsCFQAAAAAdAAAAABAd). Please update your model simulation and associated context accordingly.</p><p>7. Page 17 Figure 6. Same issue as Figure 5e and 5f, with the model simulated regimen, we are not supposed to expect more B cell depletion in lymph node and spleen compared to that in bone marrow.</p><p>8. Page 20 Figure7. You may consider alternative regimens (e.g., high dose intensive treatment initially, followed by lower dose, less intensive treatment for consolidation) given that E:T ratio is expected to increase substantially following initial treatment.</p><p>9. Figure 5—figure supplement 3C. I'm not sure if the conclusion that &quot;bidirectional effect was shown by increasing B cell density, owing to enhanced probability of cell-cell encounter and then insufficient BiTE concentration&quot; hold true, given that for each individual B cell, the opportunity of encounter blinatumomab and T cells should be the same even at lower B cell concentrations.</p><p>10. Figure 4—figure supplement is missing</p><p>11. Given that you have 17 supplementary figures, please include a separate file where all the figures and the respective figure legends will be arranged together when you submit the revised article.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. More details regarding the estimation of model parameters should be provided. Specifically, details of the type of the cost function used, confidence intervals, and the sensitivity of the in vivo dosage strategies to the chosen parameter values. It was not clear if a killing rate for tumors was used and whether it was estimated. Do the T cells proliferate/die in the in vivo model? A clear discussion of the data that were used to train the model (e.g., to estimate parameters) and test predictions should help.</p><p>2. It might help to further evaluate the importance of the cell population level interactions added in the model if one of the existing models in the literature was compared against the model developed here for describing the in vitro and in vivo experiments.</p><p>3. I think an experimental test of the surprising results in supplementary Figure 3a will substantially increase the confidence in the model.</p><p>4. It will help the readers to follow the model if model parameters were shown in the figures (e.g., Figure 5a).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83659.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Cell adhesion molecules are regulated by TCR are not explicitly included in the model. Do the author feel that BITEs are not triggering these mechanisms or that their action is directly related to BiTE mediated interactions that are explicitly modelled such that the contributions of adhesion are included in the contributions of the BiTE interactions.</p></disp-quote><p>We agree with the reviewer that adhesion molecules play critical roles in synapse formation. In our model, we assumed these adhesion molecules were constant and comparable across cell populations. This assumption allowed us to focus on the BiTE-mediated interactions.</p><p>To clarify this point, we added a few sentences in the manuscript:</p><p>“Adhesion molecules such as CD2-CD58, integrins and selectins, are critical for cell-cell interaction. The model did not consider specific roles played by these adhesion molecules, which were assumed constant across cell populations. The model performed well under this simplifying assumption.”</p><p>In addition, we acknowledged the fact that “synapse formation is a set of precisely orchestrated molecular and cellular interactions. Our model merely investigated the components relevant to BiTE pharmacologic action and thereby serve as a simplified representation of this process”.</p><disp-quote content-type="editor-comment"><p>2. T cell movements in tissue is not a random walk, but is scaffolded by stromal cells and extracellular matrix to generate a variety of search strategies, which have been reported in the literature. Do any of the surprising results from the model potentially arise from known, non-Brownian aspects of T cell migration in tissues (or from aspects of cell adhesion in tissues that are not linear related to BiTE mediated interactions).</p></disp-quote><p>We agree that the tissue stromal factors greatly influence the patterns of T cell searching strategy. Our current model considered Brownian motion as a good first approximation for two reasons: (1) we define tissues as homogeneous compartments to attain unbiased evaluations of factors that influence BiTE-mediated cell-cell interaction, such as T cell infiltration, T: B ratio, and target expression. The stromal factors were not considered in the model, as they require spatially resolved tissue compartments to represent the gradients of stromal factors; (2) our model was primarily calibrated against in vitro data obtained from a “well-mixed” system that does not recapitulate specific considerations of tissue stromal factors. We did not obtain tissue-specific data to support the prediction of T cell movement. This is under current investigation in our lab. Therefore, we are cautious about assuming different patterns of T cell movement in the model when translating into in vivo settings. We acknowledged the limitation of our model for not considering the more physiologically relevant T-cell searching strategies.</p><p>In the Discussion, we added a limitation of our model: “We assumed Brownian motion in the model as a good first approximation of T cell movement. However, T cells often take other more physiologically relevant searching strategies closely associated with many stromal factors. Because of these stromal factors, the cell-cell encounter probabilities would differ across anatomical sites.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The authors use Jurkat-Raji combination for imaging flow cytometry. Jurkat is likely to use the CD2-CD58 adhesion system to engage Raji and this could be investigated with antibodies to CD2 or CD58. It is not clear to me how the simple use of blinatumomab bridge formation can correctly model the adhesion process. I suspect this works because the CD2-CD58 system is likely to be a constant and the frequency of blinatumomab Bridges is controlling signaling that promoted CD2-CD58 interaction to mediate conjugate formation and observed actin polymerisation. So the modelling may be correct in predicting the bell shape, but would not hold up if the physical requirements for synapse formation were correctly modelled. So the inclusion of CD2-CD58 and other adhesion systems may not change some aspects of the models, but it would provide another escape route for the tumour- through CD58 loss rather than CD19 loss.</p></disp-quote><p>We appreciate the suggestions on the adhesion model and motility pattern. Adhesion is a very complex process containing a lot of signaling and functional proteins. We agree that the CD2-CD58 adhesion is critical for cell-cell interaction. Unfortunately, CD58 expression across cell populations was not quantified in our experiments and our model assumed these adhesion molecules stay constant as a part of the BiTE-mediated interactions. In our model, the adhesion probability is approximated as a function of trinary complexes (BiTE bridging). Such approximation significantly reduced the computational complexity but retain sufficient accuracy. The stochastic nature of the model does account for the influence of other molecules, like CD2-CD58 interaction. However, we did not explicitly put these molecules into our model for quantitative evaluation. We have stated this within the text as a model assumption and limitation.</p><p>We added the following contents into our manuscript. “Adhesion molecules such as CD2-CD58, integrins and selectins, are critical for cell-cell interaction. The model did not consider specific roles played by these adhesion molecules, which were assumed constant across cell populations. The model performed well under this simplifying assumption.”</p><disp-quote content-type="editor-comment"><p>Understanding the competition between adhesion and motility in the tumour may be important to understand the dissociation process. So chemokinesis may be an important thing to consider that may different in different settings. Due to chemokine like CXCL12 and CCL19/21 it may be very strong in lymphoid tissues, but bone marrow and other tissues may have very different landscapes of chemokine and thus the drive to disengage from a target may be lower or higher.</p></disp-quote><p>This is a great point. Although our model did not consider chemokines like CXCL12 and CCL19/21, these chemokine gradients likely alter the kinetics of engagement/disengagement in a tissue-specific manner. As demonstrated, differences in T cell infiltration and T: B ratios across anatomical sites create sanctuary sites for tumor cells in the host. The different landscapes of these chemokines across tissues would make certain sanctuary sites, like the bone marrow, more likely to manifest.</p><p>We have added the following content to the discussion. “The inadequate tumor lysis in the bone marrow might also be explained by tissue-specific differences chemokine gradients that hinder cell-cell interaction and adhesion.”</p><disp-quote content-type="editor-comment"><p>In terms of search models, the actual movement pattern will depend upon the underlying stroma. In a lymph node this network allows for frequent turns and exploration of the 3D space, where in some tumours the stroma may be more oriented and may convey T cells toward or away from the tumour. In the CNS, Lévy flight was found to be more efficient than a random walk would have been. Can this complexity explain any situation where the model predictions didn't hold?</p></disp-quote><p>We agree that T cell motility is quite different between in vitro and in vivo settings, as well as across anatomical sites. Random search is merely an approximation of T cell behaviors in our model and we agree that tissue stromal factors greatly influence the patterns of T cell searching strategy. Our current model considered Brownian motion as a good first approximation for two reasons: (1) we define tissues as homogeneous compartments to attain unbiased evaluations of factors that influence BiTE-mediated cell-cell interaction, such as T cell infiltration, T: B ratio, and target expression. Stromal factors were not considered in the model, as they often need spatially resolved tissue model to accommodate the gradients of these stromal factors; (2) our model was primarily calibrated against in vitro data obtained from a system without tissue stromal factors, and we did not obtain tissue-specific data in this study to support the predictions of T cell movement patterns influenced by these stromal factors. This is under current investigation in our lab. Therefore, we are cautious about assuming different T cell movement patterns in the model when translating BiTE-mediated cell-cell interactions from in vitro to in vivo settings. We acknowledged the limitations of our model for not considering the more physiologically relevant T-cell searching strategies.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. What is the major purpose of modeling the immune synapse variants? Are they expected to have clinical significance (e.g., increase /decrease in efficacy, induce tumor antigen escape)?</p></disp-quote><p>This is a great point. Immune synapse variants account for 9.7 ~ 50.1% of total IS, depending on the experimental conditions. These variants cannot be ignored, especially at high cell density and high E: T ratio (Figure 4a, condition 5 and 11). It remains unclear how frequently cell clustering occurs in vivo, as well as what drives it; we speculate that cell clustering (e.g., ETEE) may yield a higher killing efficiency as shown in an efficacy study (Gong et al. 2019). This aligns intuitively with higher E:T ratios being associated with greater tumor killing in both in vitro and in vivo systems; there is simply a greater density of effector cells in the system, increasing the likelihood of interaction through Brownian motion. Our model does not differentiate the killing efficiency of these synapse variants, but the model does provide a framework for us to address these questions in the future.</p><disp-quote content-type="editor-comment"><p>2. In page 10 Figure 3, the incubation system was defined with X x 10E6 cells/mL, does this refer to total cell numbers (i.e., E + T cells), effector cells numbers or target cell numbers, please clarify in the figure legend for each respective experimental condition (e.g., Figure 3h and 3i, when you have different E:T ratios).</p></disp-quote><p>It refers to total cell numbers (E+T cells).</p><p>We have added this clarification in the figure legend, like “2X, 2x10^6 total cells/mL”</p><disp-quote content-type="editor-comment"><p>3. In page 10 Figure 3h, I would like recommend separation of effector cells and target cells, given that engagement of target cells is expected to be more clinically relevant.</p></disp-quote><p>Thank you. Figure 3i and the original Figure 3-supplement 1 show separated curves for the percentages of effector cells and target cells engaged in immunological synapses. We have removed Figure 3h and replaced by original Figure 3-supplement 1.</p><disp-quote content-type="editor-comment"><p>4. In page 12 line 233, it was stated that &quot;IS formation was optimized when the E:T ratio was around 1&quot;. Given that a lot of in vitro studies a conducted using E:T ratio 5:1 or 10:1, do you think your simulation results can be used to modify the in vitro study experimental condition towards better outcome?</p></disp-quote><p>A great point, it was misleading as shown in our original Figure 3h and the above statement.</p><p>To avoid confusion, we have removed Figure 3h and replaced by original Figure 3-supplement 1. To provide an explanation, “E:T ratio around 1”, is the optimized condition that yielded the highest fraction of total cells engaged in an IS, not the fraction of target cells. We agree that it is not a good indicator of clinical outcome. In contrast, the fraction of target cells engaged is expected to be lower at 1:1 ET ratio than at a higher E: T ratio (Figure 3i). Using higher E:T ratios (e.g., 5:1 or 10:1) would clearly maximize killing efficacy.</p><disp-quote content-type="editor-comment"><p>5. Page 15 Figure 5c and 5d, do you have any observed data to verify the model simulated reduction in CD19 expression level following blinatumomab treatment?</p></disp-quote><p>We did not experimentally verify CD19 evolution in our in vitro system, as the timescale for immunological synapse formation was too short to expect adaptation and CD19 negative “relapse” (1 hr). Considering T-cells are serial killers of tumor cells, we did not extend our observation to a longer duration as it would prevent an accurate quantification of immunological synapses. However, antigen escape has been a tumor resistance mechanism broadly observed in the literature (Xu et al., 2019; Mejstríková et al., 2017; Samur et al., 2021).</p><p>We have cited these references and meanwhile acknowledged that more validations of our models are warranted.</p><disp-quote content-type="editor-comment"><p>6. Page 15 Figure 5e and 5f, one major concern for me is that your model simulation suggested that the bispecific is more effective in spleen and bone marrow compared to that in bone marrow, which generally against the clinical observation (e.g., the expected efficacious dose of blinatumomab for Acute Lymphoblastic Leukemia [major site of action is bone marrow] and Non-Hodgkin's Lymphoma [major site of action is lymph node] are 15 ug/m2/day vs. 60 ug/m2/day, respectively), and animal data (e.g., MGD-011 showed much strong B cell depletion effect in bone marrow compared to that in spleen and lymph node, PMID: 27663593). This may be associated with the heterogenous distribution of T cells and B cells in the lymph node and spleen (https://www.google.com/url?sa=iandurl=https%3A%2F%2Fimmunox.ucsf.edu%2Fsites%2Fimmunox.ucsf.edu%2Ffiles%2Fpdf%2FMicro204_Anat_IR%2520v2018.pdfandpsig=AOvVaw0qOMQka3SNN7k762B84FYDandust=1670808103053000andsource=imagesandcd=vfeandved=0CBAQjhxqFwoTCLC0za2z8PsCFQAAAAAdAAAAABAd). Please update your model simulation and associated context accordingly.</p></disp-quote><p>Thank you for providing this information. It is very helpful for us to justify our model assumptions. We agree that the heterogeneous distribution of T and B cells can reduce drug efficacy. Meanwhile, as shown in Reviewer 1 comments, the bone marrow has very different chemokines and a dense stromal structure, which may reduce T cell mobility and functionality. Because of these aspects, the bone marrow often has reduced drug efficacy, consistent with our model prediction. However, it remains to be determined which organs restrict drug efficacy to the highest degree. We suggest that the bone marrow could be an organ that contributes to tumor evolution, consistent with literature showing that tumor relapses are often firstly detected in the bone marrow. One recent paper published in PLoS Com Bio also showed reduced efficacy in the bone marrow (Yoneyama et al., 2022). This is an issue for further clarification and confirmation.</p><p>To acknowledge the inconsistent observations, we added the following content, “Our models only considered a few select factors that influence the formation of IS, which may not provide a full description of drug inhomogeneous efficacy across anatomical sites. Factors like the heterogeneous distribution of T and B cells, chemokines, and stromal structures could affect the T cell motility and functions in tissue environments and including these factors may provide an unbiased evaluation of drug effect across tissues.”</p><disp-quote content-type="editor-comment"><p>7. Page 17 Figure 6. Same issue as Figure 5e and 5f, with the model simulated regimen, we are not supposed to expect more B cell depletion in lymph node and spleen compared to that in bone marrow.</p></disp-quote><p>Thank you for this point. We have made some adjustment in our manuscript and details of the explanation is provided in the last question.</p><disp-quote content-type="editor-comment"><p>8. Page 20 Figure7. You may consider alternative regimens (e.g., high dose intensive treatment initially, followed by lower dose, less intensive treatment for consolidation) given that E:T ratio is expected to increase substantially following initial treatment.</p></disp-quote><p><bold>:</bold> In agreement with reviewer’s suggestion, we simulated alternative dosing regimens with high dose followed by medium dose and medium dose followed by low dose (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). At the given scenario, the alternative dosing regimen (dashed lines) does not perform as well as its counterpart dosing regimen (constant dose levels, solid lines). Although E:T ratio is expected to be high following the initial high doses in the first 2 cycles, the change of medium dose (dashed blue line) provides even less effect compared with constant medium dose (solid red line) since week 12. This is attributed to more CD19 loss after initial high dose compared with constant medium dose. Therefore, alternative regimen is not supported by our current model assumptions to maintain a comparable killing effect with constant high or medium doses.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83659-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>9. Figure 5—figure supplement 3C. I'm not sure if the conclusion that &quot;bidirectional effect was shown by increasing B cell density, owing to enhanced probability of cell-cell encounter and then insufficient BiTE concentration&quot; hold true, given that for each individual B cell, the opportunity of encounter blinatumomab and T cells should be the same even at lower B cell concentrations.</p></disp-quote><p>We agree the expression is not clear. “Probability of cell-cell encounter” in the text actually indicates the overall probability for the population (T and B cells) not the individual B cell. When the T cell density is constant, the probability for each B cell encountering a T cell is independent of B cell density. At the population level, however, cell-cell encounter probability depends on both T cell and B cell density. At a higher B cell density, the probability for each T cell encountering a B cell stays high.</p><p>To avoid confusion, we revised this conclusion as “bidirectional effect was shown by increasing B cell density, owing to enhanced probability of cell-cell encounter at the population level and then insufficient BiTE concentration.”</p><disp-quote content-type="editor-comment"><p>10. Figure 4—figure supplement is missing</p></disp-quote><p>There is no supplement for figure 4, and Figure legends have been added to avoid confusion.</p><disp-quote content-type="editor-comment"><p>11. Given that you have 17 supplementary figures, please include a separate file where all the figures and the respective figure legends will be arranged together when you submit the revised article.</p></disp-quote><p>This is a good point. A separate arrangement of the supplementary figures and tables (Supplementary Materials) will be reviewer friendly. We have made the adjustments.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. More details regarding the estimation of model parameters should be provided. Specifically, details of the type of the cost function used, confidence intervals, and the sensitivity of the in vivo dosage strategies to the chosen parameter values. It was not clear if a killing rate for tumors was used and whether it was estimated. Do the T cells proliferate/die in the in vivo model? A clear discussion of the data that were used to train the model (e.g., to estimate parameters) and test predictions should help.</p></disp-quote><p>We did not perform a global parameter optimization of our models considering the stochastic agent-based nature of the models. However, the majority of key parameters was obtained or derived from the literature, such as 3D dissociation constant (supplementary file 1a), 2D on/off rate constant (derived, supplementary file 1a and Appendix 1.5), encounter probability (supplementary file 1a, Appendix 1.3), and CD19 internalization (supplementary file 1a). CD3 and CD19 distributions on cell surface (supplementary file 1a) were exactly aligned with our observation (Figure 1—figure supplement 1). IS variant formation and spatial coefficient were based on our observation and derived from spatial configuration (supplementary file 1a, Appendix 1.3). The data from our pilot studies were used to estimate the parameters in CD3 down-regulation (r and h in supplementary file 1a) and adhesion probability (β in supplementary file 1a) in our base model. Our in-vivo model for clinical prediction adopted the same parameter values from the base model and the in-vitro model. Newly added patient-specific parameters such as cell density in organs, cell turnover rate, cell trafficking rate, antigen expression, and drug distribution were all from literatures and clinical reports (supplementary file 1b and c). The only parameter we manually optimized in the in-vivo model is the sensitive coefficient (β in supplementary file 1b) for cell-cell adhesion and the value was re-calibrated against the in-vitro data at a low BiTE concentration. BiTE concentrations in patients (mostly &lt; 2 ng/ml) is only relevant to the low bound of the concentration range we investigated in vitro (0.65-2000 ng/ml).</p><p>About T cells proliferate/die and killing rate, the response has been provided previously.</p><p>We added a discussion of our model limitation to clarify these points:</p><p>“The majority of model parameters were obtained or derived from the literature, and we did not perform model optimization to get the optimal values of model parameters. The only parameter we manually optimized is the sensitive coefficient for cell-cell adhesion in the base and in-vivo model and the values were calibrated against the in-vitro data. Implementing model optimization algorithms would improve the predictability of the models.”</p><disp-quote content-type="editor-comment"><p>2. It might help to further evaluate the importance of the cell population level interactions added in the model if one of the existing models in the literature was compared against the model developed here for describing the in vitro and in vivo experiments.</p></disp-quote><p>This is an interesting point, but it is challenging to make direct comparison of our models with literature models because of different methods and model objectives. We have cited most if not all literature models. Our model focused on understanding the factors driving IS formation and tested if these driving factors play important roles for BiTE clinical pharmacodynamics and tumor evolution. Literature models were mostly developed to describe the concentration-dependent cytotoxic effect of BiTE antibodies. All models predicted bell-shaped relationships and concentration dependency. Our models yield additional insights concerning IS synapse formation dynamics, tumor evolution, and non-homogeneous effects across anatomical sites. These insights could benefit our understanding of clinical responses and optimal doses.</p><disp-quote content-type="editor-comment"><p>3. I think an experimental test of the surprising results in supplementary Figure 3a will substantially increase the confidence in the model.</p></disp-quote><p>Thank you for pointing this out. Supplementary Figure 3a illustrates the influence of CD3 affinity on the fraction of effector cells engaged in IS formation. High CD3 affinity counterintuitively decreases the fraction of effector cells in IS formation due to (1) rapid CD3 downregulation upon BiTE engagement; (2) more BiTE antibodies consumed per IS because of the high affinity. In addition, the influence of CD3 affinity on cytotoxic effect is not quite consistent in the literature and there are papers reporting that high CD3 affinity may result negative effect on BiTE cytotoxic effects (Chen et al., 2021; Dang et al., 2021). We have cited these papers in the manuscript and believe they support our predictions.</p><disp-quote content-type="editor-comment"><p>4. It will help the readers to follow the model if model parameters were shown in the figures (e.g., Figure 5a).</p></disp-quote><p>Thank you for the suggestion, we have added IS duration (150 min), encounter probability (Pe), and adhesion probability (Pa) to Figure 5a; B cell turnover rate (k<sub>B cell</sub>), and B cell trafficking rate (k<sub>traff, in</sub> and k<sub>traff, out</sub>) to Figure 6a.</p><p>References:</p><p>Chen W, Yang F, Wang C, Narula J, Pascua E, Ni I, Ding S, Deng X, Chu ML, Pham A, Jiang X, Lindquist KC, Doonan PJ, Blarcom TV, Yeung YA, Chaparro-Riggers J. 2021. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics. <italic>MAbs</italic> 13:1871171. DOI: 10.1080/19420862.2020.1871171, PMID: 33557687</p><p>Dang K, Castello G, Clarke SC, Li Y, AartiBalasubramani A, Boudreau A, Davison L, Harris KE, Pham D, Sankaran P, Ugamraj HS, Deng R, Kwek S, Starzinski A, Iyer S, Schooten WV, Schellenberger U, Sun W, Trinklein ND, Buelow R, Buelow B, Fong L, Dalvi P. 2021. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. <italic>Journal for ImmunoTherapy of Cancer</italic> 9:e002488. DOI: 10.1136/jitc-2021-002488, PMID: 34088740</p><p>Gong C, Anders RA, Zhu Q, Taube JM, Green B, Cheng W, Bartelink IH, Vicini P, Wang BPopel AS. 2019. Quantitative Characterization of CD8<sup>+</sup> T Cell Clustering and Spatial Heterogeneity in Solid Tumors. <italic>Frontiers in</italic> Oncology 8:649. DOI: 10.3389/fonc.2018.00649, PMID: 30666298</p><p>Mejstríková E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM, Zugmaier G, Gore L, Stackelberg AV, Locatelli F. 2017. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. <italic>Blood Cancer Journal</italic> 7: 659. DOI: 10.1038/s41408-017-0023-x, PMID: 29259173</p><p>Samur MK, Fulciniti M, Samur AA, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. 2021. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. <italic>Nature Communications</italic> 12:868. DOI: 10.1038/s41467-021-21177-5, PMID: 33558511</p><p>Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S, Li Y. 2019. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. <italic>Frontiers in Immunology</italic> 10:2664. DOI: 10.3389/fimmu.2019.02664, PMID: 31798590</p><p>Yoneyama T, Kim MS, Piatkov K, Wang H, Zhu AZX. 2022. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma. <italic>PLOS Computational Biology</italic> 18: e1009715. DOI: 10.1371/journal.pcbi.1009715, PMID: 35839267</p></body></sub-article></article>